The interaction of neutrophils and amyloid-ß in Alzheimer’s disease by Hill, Madison Jean






















A thesis submitted in partial fulfilment of the Degree of 
Bachelor of Biomedical Science with Honours. 







Alzheimer’s disease (AD) is a progressive neurodegenerative disorder that affects memory and 
cognition. A key molecular pathological hallmark of AD is amyloid-ß deposition. Amyloid-ß 
is a small aggregation-prone peptide that forms the senile plaques characteristic of AD. 
Although amyloid-ß has long been a focus of AD research, clinical trials targeting the 
aggregation and deposition of the peptide have been largely unsuccessful. The shift away from 
amyloid-ß focused research and advancements in genetic profiling have enabled the discovery 
that many of the genes affected in sporadic AD are related to immunity. Neuroinflammation is 
now accepted as another of the key pathological hallmarks of AD; however, the exact 
mechanisms of how it contributes to disease onset are still undetermined.  
Recent literature has shown that peripheral innate immune cells, such as neutrophils, contribute 
to AD pathology. Neutrophils invade the central nervous system in AD and undergo an immune 
response called NETosis, where they form networks of extracellular fibres, composed of DNA 
decorated with granule proteins. The formation of these neutrophil extracellular traps (NETs) 
has been previously shown to occur around amyloid-ß plaques. The precise interaction between 
neutrophils and the amyloid-ß deposits is unknown, but NETs may modify the immunological 
and biochemical properties of the plaques.  
Thioflavin T fluorescent assays and electron microscopy were used to characterise and validate 
four different multimerization states of amyloid-ß42. These represent the different species 
found in the AD brain. Neutrophils were isolated from human blood and NETosis was induced 
using phorbol myristate acetate (PMA). Using a SYTOX™ green assay to measure NETosis, 
it was observed that amyloid-ß42 does not induce NET formation in neutrophils, irrespective 
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of aggregation state or the presence of complement factors in serum or anti-amyloid-ß 
antibodies. Using immunocytochemistry and fluorescent microscopy, the binding of amyloid-
ß42 to NETs was observed in an in vitro system. When micrococcal nuclease was used to 
degrade the DNA structure of NETs, a reduction was found in the binding of heavily aggregated 
amyloid-ß42 species to NETs. This reduction indicated that the binding between heavily 
aggregated amyloid-ß42 and NETs is likely mediated by the NET-DNA matrix. Microglia are 
the resident immune cells of the brain and were seen to interact with both NETs and all species 
of amyloid-ß42. This interaction could indicate that NET-plaque complexes are involved in 
initiating an immune response and contribute to the neuroinflammation seen in the AD brain. 
Binding with amyloid-ß plaques could enable the persistence of NETs in the AD brain. 
Furthermore, NETs changing the plaque structural or chemical properties could potentially 
contribute to the chronic inflammation seen in AD patients. Therapeutics focused on inhibiting 
or depleting neutrophil entry into the central nervous system, or preventing the formation of 
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Chapter 1: Introduction 
 
1.1 ALZHEIMER’S DISEASE 
Alzheimer’s disease (AD) was first described in 1906 by Dr. Alois Alzheimer who noticed 
abnormalities in the brain tissue of an insane asylum patient (1). Alzheimer’s post-mortem brain 
examination of this patient described neurofibrillary tangles and “miliary foci” (1). It was not 
until many decades later that researchers were able to isolate the main molecular components 
of these irregularities identified by Alzheimer. The neurofibrillary tangles were found to be 
made up of a hyperphosphorylated form of a microtubule-associated protein, named tau. (2). 
The “miliary foci” are now described as amyloid plaques, which are mainly composed of a 
small, aggregation prone peptide named amyloid-β (Aβ) (3).  
Although these two proteins are heavily implicated in AD pathology, they are not the only 
causative abnormalities that contribute to disease onset. Other pathological hallmarks of AD 
include inflammation, neuronal cell loss, and neurovascular damage (4). Due to these changes 
in the brain, AD patients experience cognitive decline, memory loss and altered behavior (4). 
It is estimated that the prevalence of the disease in the world for those over 65 is 10-30%, and 
with a rising elderly population the number of cases is expected to double by 2050 (4).  
Current treatment for AD is minimal and largely ineffective due to uncertainty around the 
primary causes of the disease in its sporadic form (5). Fewer than 1% of cases are familial, with 
these being primarily driven by mutations in genes that affect Aβ processing (5, 6). Although 
the familial cases make up the minority, they are beneficial in studying the development of the 
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disease over time. There is less understanding around the molecular mechanisms that cause 
sporadic AD (sAD), also known as late-onset AD (LOAD). Recent studies have linked many 
genes involved in neuroinflammation to the onset of sAD (6–8), and this has contributed largely 
to shifting the focus in the AD field from Aβ to wider contributors of pathogenesis, such as 
neuroinflammation.  
Current drugs can provide some symptomatic relief; however, studies focused on developing 
disease modifying drugs have been widely unsuccessful (9). Research has largely focused on 
anti-amyloid therapies, but as understanding of AD pathology increases, it has become apparent 
that multi-target therapy will need to be utilized for treatment. The recognition of 
neuroinflammation as an increasing factor involved in AD onset, and failure of anti-amyloid 
therapies indicates that the later phases of AD are amyloid-independent. To be able to better 
treat AD a more comprehensive understanding of its pathogenesis is needed. 
 
1.2 AMYLOID-ß 
One of the major hallmarks of Alzheimer’s disease is the deposition of Aβ aggregates in the 
brain parenchyma and cerebral blood vessels. The isolation of the Aβ peptide was one of the 
first major breakthroughs in understanding the molecular events that led to AD pathogenesis. 
The biochemical purification of Aβ was originally achieved by Glenner and Wong (3) and later 
by Masters et al. (10). The peptide was described as having a molecular weight of around 4kDa 
and strong tendencies to aggregate (3, 10). The theory that Aß was the product of a cleavage 
event from a larger species was confirmed by Kang et al. who cloned what is now known as 
the amyloid precursor protein (APP) (11). The APP is cleaved sequentially by β and γ–secretase 
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enzymes to form the shortened Aβ peptide (12). The cleavage is imprecise and results in a 
variety of peptide lengths, ranging between 38 and 43 amino acid residues (12). Although the 
most abundant peptide variant in the body is Aβ40, plaques are mainly composed of the less 
abundant Aβ42. This is because the 42 residue form of the peptide is much more aggregation 
prone (12–14). The greater propensity to aggregate is potentially due to the C-terminus of the 
Aß42 peptide being more inherently structured, as the extra residues allow for the formation of 
a ß-hairpin, reducing peptide flexibility (14).  
 
Figure 1.2.1: Amyloid Precursor Protein (APP) processing to form various lengths of Aß. The APP is cleaved 
from the cell membrane sequentially by ß and γ-secretases, leaving the newly formed Aß peptide. The secretase 
cleavage is imprecise which results in a mixture of peptide lengths. Hill, 2020, original work. 
 
The peptides are able to form ordered β-pleated sheet structures that are highly fibrillogenic. 
Eventually, these can become large aggregated masses, forming the amyloid plaques 
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characteristic of AD. It is important to note that amyloid plaques do not only contain Aß. Earlier 
research by Liao et al showed enrichment of 26 proteins in plaques from 2 participants (15). 
Drummond et al. broadened this research by carrying out a study where plaques were extracted 
from 44 participants and used for comparison of different subtypes of AD (16). Not only did 
they find consistent enrichment of over 279 proteins across all plaques, they also discovered 
different subtypes of AD have different plaque protein compositions (16). When studying the 
mechanisms of plaque formation, or testing drugs targeted against plaque formation, it is 
important to consider that these proteins may have roles in pathogenesis.  
Aβ42 aggregation kinetics have become better understood through animal models (17–20) and 
it has been shown that Aβ42 aggregates can seed deposition of other peptide variants such as 
Aβ38-40 (13, 21). As well as fibrils, Aβ oligomers have recently been suggested to play a role 
in AD pathology (22). Mouse models that produce mutant forms of Aβ that undergo 
oligomerisation but not fibrilization show that oligomers accumulate within neurons in the 
hippocampus and cerebral cortex, causing significant memory impairment (17). Oligomers 
were also shown to activate microglia and astrocytes, key immune cells within the brain, even 
in the absence of amyloid plaques (17). Although not all classical hallmarks of AD are observed 
in the mouse model that was used for this study, the research provides strong evidence that Aβ 




Figure 1.2.2: Aggregation pathway of Aß42. The pathway begins with single monomers of the 42-residue 
peptide. When misfolded, these can come together to form oligomers and eventually protofibrils. The fibrillar 






1.2.1 The Amyloid Cascade Hypothesis 
The amyloid hypothesis proposed by Hardy and Higgins in 1992 (23) still provides much of 
the framework for studying AD pathogenesis. The hypothesis suggests that Aβ deposition 
causes all of the other pathological hallmarks observed in AD patients, such as cell loss, 
vascular damage, and neurofibrillary tangles (23). Clinical studies have shown that plaque 
formation can occur decades before the onset of dementia symptoms (24, 25), which some 
argue is evidence supporting the amyloid cascade hypothesis. However, many of these studies 
rely on the participation of subjects with familial histories of AD, which make up only a small 
percentile of total AD cases. More than 95% of Alzheimer’s cases are sporadic (4), and this 
makes it harder to determine the timeframe of amyloid plaque formation.  
A recent study extended Aß deposition research to sAD by monitoring ‘normal’ participants 
over a 7 year period (26). They found successive changes in Aß and tau were associated with 
lower cognition (26). However, there were significant limitations to the study, including a small 
cohort, which prevents generalisation of the findings (26). Larger studies are required to form 
further hypotheses about sAD pathogenesis. Some argue that there is literature bias favouring 
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the amyloid hypothesis which plays a large factor in the consistent therapeutic failures seen in 
the field (27). The basis of the amyloid hypothesis relies on familial studies concluding that the 
over production of Aβ, due to genetic mutations, causes AD (28–30). However, there are no 
studies that prove sAD is caused by the overproduction of Aβ (27), meaning the hypothesis is 
not as relevant to the more common form of the disease.  
Dominantly inherited mutations in the APP, PSEN1, and PSEN2 genes are commonly 
associated with familial AD (fAD) (28). Presenilin 1 (PSEN1) and presenilin 2 (PSEN2) are 
protein components of the γ secretase enzyme involved in APP cleavage. Genetic mutations in 
these genes can result in higher ratios of Aβ42 to Aβ40, or produce more Aβ altogether, which 
speeds up the process of Aß aggregation and plaque formation in the brain (29, 30). Many of 
the genes implicated in sAD are also related to Aβ, but they are more to do with clearance or 
degradation than enhanced production (6). Aβ is naturally cleared from the central nervous 
system (CNS) into the cerebrospinal fluid (CSF), but with neurodegeneration and aging this 
clearance can be impaired (31).  
It is common to have the presence of Aβ deposits in the brain without experiencing any 
symptoms of AD (24). Around 40% of non-demented elderly fit the neuropathological criteria 
for AD based on their Aβ plaque burden (32). This creates controversy around the amyloid 
cascade hypothesis and calls for suggestion of other theories that may include pathological 
processes not focused around amyloidosis and Aβ deposition. Due to this poor correlation 
between Aß burden and dementia symptoms, questions remain as to what processes are 
necessary for patients to progress from amyloidosis to neurodegeneration. As 
neuroinflammation is also a key pathological hallmark in AD (33, 34), research on the 
downstream effects of Aß aggregation on brain and immune cells could better understanding 
of AD pathogenesis mechanisms.  
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1.3 NEUROINFLAMMATION  
Despite a strong focus on amyloid pathology in clinical research, and even some success in Aß 
plaque reduction (35), treatment is yet to be developed that can alter or prevent disease onset. 
This suggests that other factors are playing a role in the development of AD. As research has 
progressed with time, many studies have found evidence that neuroinflammation is involved in 
AD pathology. Furthermore, links have been found between chronic inflammation in the brain 
and Aß deposition (34). Neuroinflammation changes the immune landscape in the CNS 
dramatically. Not only are resident immune cells activated, but peripheral immune cells are 
able to penetrate the blood brain barrier (BBB). The BBB is a highly selective border of 
epithelial cells that is only semipermeable to prevent blood molecules and cells from crossing 
over into the brain CNS (36). However, chronic inflammation in AD can lead to BBB 
breakdown and leakage (36). Researchers in the 1980s reported the presence of immune-related 
proteins or cells around amyloid plaque sites (30, 31) and recent studies have reported 
infiltration of blood-derived immune cells into the brain parenchyma (32, 33). 
 
1.3.1 Sporadic AD genetic risk factors  
Many of the genetic risk factors that have been discovered for sAD relate to immune processes. 
A variant of the gene that codes for apolipoprotein E, APOE ε4, is the strongest known risk 
factor for developing sAD (6, 41). Apolipoprotein E (APOE) is a glycoprotein that is involved 
in lipid metabolism and is strongly upregulated in microglia responding to damage (41). APOE 
has also been found within Aβ plaques (7). It is estimated that the APOE 4 allele is responsible 
for at least 50% of sAD cases (4). Genome-wide association studies have enabled scientists to 
find further genes that can have polymorphisms associated with sAD. Hits include CR1, CD33, 
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TREM2, and SPI1, with many of these genes being important for immune processes such as 
phagocytosis or antigen presentation (8). These upregulated genes show that inflammatory 
mechanisms play a key role in the onset of sAD, and suggests the immune system may be 
implicated in the initiation and severity of neurodegeneration. Furthermore, this genetic 
information supports the movement away from treatments focusing solely on Aβ deposition, 
and instead promotes a focus on the immune system response to amyloidosis. 
 
1.3.2 Mediators of inflammation  
Microglia are the resident immune cells of the CNS and migrate to sites of injury or 
inflammation to initiate an immune response. When chronically activated, microglia produce a 
range of proinflammatory molecules such as reactive oxygen species (ROS) and cytokines (34). 
They have been shown to migrate towards and phagocytose Aβ oligomers and fibrils via 
receptor-mediated interactions (42, 43). Microglia have also been shown to take on a damage-
associated microglia (DAM) phenotype when in close proximity to amyloid plaques (44, 45). 
This pathological phenotype causes expression of high levels of immune receptors such as 
CD11c and CD14 which can drive inflammation and recruit other immune cells such as 
neutrophils (45). DAMs have been shown to display a type 1 interferon response which causes 
further inflammation and activation of the immune system (46). This type 1 interferon response 




1.3.3 Immune cell response to Aβ 
Investigating the immune cell response to Aβ species in vitro can be difficult as results often 
conflict with in vivo research. Some reports indicate that pure Aβ preparations do not trigger an 
inflammatory response when applied to brain cells in vitro (8), which contradicts in vivo 
findings that show inflammation occurring around the sites of amyloid plaques (44, 45, 
Rustenhoven, Smyth et al. unpublished findings). There are also conflicting reports that show 
exposure of microglia to Aβ42 aggregates increases production of pro-inflammatory cytokines 
such as interleukin 1β (IL-1β), interleukin 6 (IL-6) and tumour necrosis factor alpha (TNFα) 
(49).  
The full complexity of how cytokines and chemokines relate to neurodegeneration and AD is 
unknown, although previous research has shown that many of these immune proteins have 
effects on amyloid deposition and cognition (50, 51). IL-1β is a key mediator in the 
inflammatory response and is associated with tissue damage when involved in chronic diseases 
such as AD (52). APP/PS1 mice that carry mutations associated with fAD showed impaired 
memory and cognition due to increased microglia production of IL-1β in response to Aß 
deposits (52). The increased production of IL-1β is of further interest as it is also capable of 
upregulating expression of APP in astrocytes (53, 54). This suggests that inflammatory 
pathways potentially induced by Aß aggregates could contribute to further Aβ deposition. The 
high local concentration of IL-1β produced by microglia surrounding Aβ deposits may 
contribute to further development of AD, and therefore neuroinflammation induced by the 




1.3.4 Peripheral immune cells in AD 
Vascular cells are responsive to the inflammatory signals produced by microglia. These signals 
can induce pathological changes in the vascular system, which is a factor in the development 
of AD. Vascular Aβ oligomers and Aβ deposits induce inflammatory and morphological 
changes which can lead to impaired cerebral blood flow (CBF) (33). Endothelial cells and 
pericytes have been shown to be highly responsive to IL-1β, and this interaction has been shown 
to mediate cognitive impairment (55, 56). Many studies have shown that inflammation of the 
vascular system and impaired blood flow can contribute to cognitive decline (39, 57, 58). 
Vascular inflammation can also lead to breakdown of the BBB and allow for blood-derived 
leukocyte infiltration into the brain parenchyma (59). Migration of blood-derived immune cells, 
such as neutrophils, into the CNS can be detrimental as they can contribute to chronic 
inflammatory signals and tissue damage.  
 
1.4 NEUTROPHILS IN ALZHEIMER’S DISEASE 
1.4.1 Neutrophil biology  
Neutrophils are immune cells that are produced in the bone marrow before being released into 
circulation, where they can receive signals to migrate towards sites of inflammation (60). They 
are short lived, with a usual half-life of 6-8 hours in blood that can be extended on activation 
and migration to tissue (39, 61). Neutrophils can kill pathogens by phagocytosis or recruit other 
immune cells to aid in the resolution of inflammation (60). Antimicrobial proteins, reactive 
oxygen species (ROS) and proteolytic enzymes are all present in neutrophils to allow them to 
effectively kill invading microorganisms (60, 62).  
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Neutrophils also contain granules that are formed during cell differentiation (61). These 
granules contain specific proteins that can be released in response to infection or inflammation. 
Some of these proteins include myeloperoxidase (MPO), cathepsin G, neutrophil elastase, and 
matrix metalloproteinase-9 (MMP-9) (63). Expression of these proteins is found to be 
upregulated in patients with AD in comparison to healthy individuals (61). The neutrophil 
inflammatory response involves the release of granule proteins, which is beneficial when cells 
come into contact with bacteria as it enables them to kill the pathogen. The release of 
inflammatory signals can also recruit other immune cells to kill the pathogen. However, chronic 
inflammation can occur when the signal that recruits the neutrophils, such as plaque formation, 
is unable to be resolved. This occurs in some diseases and can cause damage to tissue 
surrounding the site of inflammation.  
 
1.4.2 Neutrophil Extracellular Traps (NETs) 
In 2004, it was shown by Brinkmann et al. that neutrophils have another antimicrobial activity 
involving the release of extracellular fibres composed of nuclear and granule constituents (62). 
These fibres, or neutrophil extracellular traps (NETs), are released by activated neutrophils 
exposed to various stimuli such as interleukin-8 (IL-8) or phorbol myristate acetate (PMA) (62). 
Although Brinkmann et al. could not be sure of the mechanisms that lead to NET release, they 
did determine the molecular composition of the NETs. DNA was proved to be a significant 
component through staining with DNA intercalating dyes and the observation that NETs were 
degraded in the presence of deoxyribonuclease (DNase) (62). Antibodies against histones 
reacted strongly with NETs, and proteins known to be present in neutrophil granules, such as 
elastase, cathepsin G, and myeloperoxidase (MPO), were also found to be associated (62). 
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NETs also contain citrullinated histone 3, as this histone modification is an important step in 
decondensing chromatin, allowing for NET release (64).  
NETs heighten the local concentration of neutrophil antimicrobial substances, thereby 
increasing the cells’ effectiveness in killing pathogens and localizing the inflammatory 
response (62). A later study by Fuchs et al. explained that the release of NETs occurred by a 
novel cell death pathway, distinct to apoptosis or necrosis (65). When activated with certain 
stimuli, neutrophils lose distinction between euchromatin and heterochromatin and all 
intracellular membranes are lost, allowing mixing of the NET components (65, 66). The 
formation of NETs is dependent on the presence of MPO and generation of ROS by 
nicotinamide adenine dinucleotide phosphate (NADPH) oxidase-2 (65, 67, 68). Neutrophils 
from human donors who are deficient in MPO are unable to form NETs (67).  
 
 
Figure 1.4.1: Bacterial induced NETosis. Neutrophils can undergo an immune response called NETosis when 
they detect pathogens, or tissue damage present in the body. When undergoing NETosis, the neutrophil loses 
distinction between euchromatin and heterochromatin, allowing DNA to be decondensed for NET release. All 
membranes are lost so the DNA and protein components of the NETs can mix and be expelled from the cell. NETs 
are predominantly made up of large strings of extracellular DNA that increase the cell surface area and allow for 
easy capture of pathogens, or localisation of inflammation. The proteases that decorate the DNA assist in the 




NETs play an important role in pathogen response, but they are also powerful mediators of 
sterile inflammation. Many of the components of NETs can be classified as damage associated 
molecular patterns (DAMPs) which are sensed by various innate immune receptors. DAMPs 
are released by damaged or dying cells and signal to the immune system that there is tissue 
injury (69). DAMPs have been shown to activate non-immune cells as well as innate immune 
cells, causing the production of various chemokines and cytokines that recruit more 
inflammatory cells (69). Components of NETs such as citrullinated histones, nucleic acids, or 
S100A8 and S100A9 proteins all signal to the body that there is tissue injury (70). In sterile 
inflammation, there is no pathogen to be removed, and it becomes less likely that the neutrophil 
response will be resolved, promoting chronic inflammation.  
 
1.4.3 NETs and disease  
Although NETs effectively trap, neutralize and kill pathogens such as bacteria, fungi, and 
parasites, they have also been found to contribute to the pathogenesis of immune-related 
diseases. Previous research has observed the release of NETs in sterile conditions (71) and 
research on NET involvement in disease is increasing with time. Papayannopoulos’ 2018 
review discusses the currently known mechanisms of NET-mediated pathology (70). These 
include tissue damage, occlusion of vasculature, modulation of sterile inflammation, and 
influencing autoimmunity (70). NETs have been shown to damage tissue by killing endothelial 
and epithelial cells which links to various types of sepsis and acute injury (70, 72, 73). NETs 
also have implications in atherosclerosis, as they modulate other immune cells which can 
directly or indirectly influence cytokines (74). Neutrophils are triggered to release NETs by 
stimuli such as cholesterol crystals at early plaque sites in the vasculature (74, 75). This 
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response recruits further immune cells, such as macrophages, which contribute to lesion size 
upon cell death.  
NETs are also linked to many autoimmune disorders, and human studies have shown NETs to 
be present in large quantities at sites of inflammation (76, 77). The release of NET granule 
proteins such as MMP-9 at these sites can damage tissue and further aggravate inflammatory 
processes (78). The impaired clearance of the NETs in these diseases drives the increased 
immune response, and this in turn prolongs the presence of active NETs and their components 
(79). Therefore, NET release can occur in the absence of microbial infection and potentially 
cause harm in a sterile environment. NETs have also recently been shown to be involved in the 
formation of gallstones (80). Neutrophils that come into contact with calcium or cholesterol 
crystals release NETs, and the extracellular DNA pulls many crystals together to form larger 
masses (80). This suggests that NETs can contribute to initiating the formation of large 
aggregates in the body that have pathological relevance.  
 
1.4.4 Neutrophils and AD 
There have been a number of studies published that have found potential, biologically relevant, 
links between neutrophils and AD pathogenesis. Dong et al. carried out a study using human 
whole blood samples to characterize neutrophil phenotypes during stages of AD (81). As well 
as finding that circulating neutrophils in AD patients produce higher levels of ROS than 
controls, they also observed significantly higher levels of circulating NETs (81). This finding 
is significant as the controls used not only included healthy controls, but controls from patients 
who had increased susceptibility to infection, and controls from patients with other forms of 
dementia. These controls exhibited normal neutrophil ROS production and normal levels of 
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circulating NETs, which suggests that highly activated neutrophils and levels of NET formation 
correlate strongly with AD. Furthermore, another study has shown that neutrophils can bind to 
and block capillary segments, which contributes to reduced cerebral blood flow in the 5XFAD 
mouse model of AD (82). Using targeted antibodies to deplete neutrophils, this study by Cruz 
Hernández et al. saw improvements in mice working memory within 24 hours (82). 
Recent research has further implicated NETs in other neurological diseases, such as strokes and 
traumatic brain injury (TBI) (83–85). NET release in a stroke model reduced vascular 
remodeling and increased BBB damage (83). NETs are associated with many proteases such as 
elastase and MPO, which can directly cause endothelial cell damage, and in turn increase 
vascular permeability (83).  Disruption of the NET formation increased vascular plasticity and 
reduced BBB breakdown, improving cognition (83). This indicates that neutrophils are 
important modulators of stroke recovery. This is important in the context of AD as stoke victims 
are more likely to develop AD as opposed to healthy individuals (86). An increased 
permeability of the BBB is strongly linked to AD (33, 34, 87) and allows for infiltration of 
neutrophils and NET formation in the CNS. NETs are also linked to worsened TBI outcomes, 
and obstruction of NET formation has been shown to improve neurological function after TBI 
(84). A study by Binet et al. found NETs were important for tissue remodeling in retinopathy 
as they targeted senescent endothelial cells for clearance (85). These studies show that NETs 
alter the working memory of mice through modulating inflammation in the nervous system, 




1.5 POTENTIAL INTERACTION BETWEEN Aß AND NETs IN AD 
Recent literature has suggested that blood-brain barrier dysfunction enables infiltration of 
blood-derived immune cells, such as neutrophils, into the brain parenchyma (39, 40, 61, 88–
90). Baik et al. observed the infiltration and accumulation of neutrophils around the sites of 
amyloid plaques in a mouse 5XFAD model (40). Using live in vivo imaging, they were the first 
to show neutrophil migration in the brain in AD, and as a result proposed that activated 
neutrophils may engulf amyloid plaques. Using 2-photon microscopy, Zenaro et al. also showed 
migration of neutrophils into the brain in AD mouse models and suggested that once inside the 
brain parenchyma, NETs were being released (39). They identified NET components such as 
MPO, neutrophil elastase and citrullinated histone H3 in mouse and human brains. Human 
neutrophils were activated by both oligomeric and fibrillar forms of Aβ42, and brains showed 
non-random distribution of MPO positive cells around the sites of amyloid plaques, meaning 
that Aβ could be acting as a chemoattractant for neutrophils to enter the brain parenchyma (39). 
This study also found that in mouse models, depleting neutrophils or blocking their migration 
into the CNS resulted in improved cognition and memory, decreased inflammation and 
decreased Aβ levels (39).  
Taking into consideration that MPO is the most abundant protein in neutrophils (60), Volkman 
et al. (90) assessed the effects of MPO deficiency in a 5XFAD mouse model. They found that 
MPO deficiency in the bone marrow reduced inflammation and prevented cognitive decline, 
even though Aβ plaque density remained the same as MPO positive controls. (90) This suggests 
that MPO may play a role in modifying AD pathology. MPO is also involved in the process of 
NETosis, therefore in the MPO deficient condition it is possible that the inability of neutrophils 
to form NETs means that the mice do not undergo damaging immune responses to amyloid 
plaques. These studies all show significant improvements in cognition by targeting neutrophil-
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mediated immunity, which suggests that treatments targeted against neutrophils may have 
potential for success in human patients. 
Further research has found that Aβ can modulate pathogen interactions with neutrophils and 
increase neutrophil response to viral infections (91). A previous study showed that 
Herpesviridae can promote Aβ fibrilization, and therefore suggested that the Aβ peptides play 
some role in CNS immunity. It was hypothesized that rapid fibrilization could be advantageous 
for capturing and inhibiting certain viruses (92). This could suggest a direct link to neutrophils 
as they also respond to viral presence and could explain the migration of neutrophils towards 
plaques.  
A recent study by Roy et al. published in 2020 found that Aβ plaques were immunogenic only 
when they contained nucleic acids (46). Plaques that did not contain nucleic acids did not elicit 
a response from microglia in vitro (46). This gives a plausible explanation for why some 
individuals may have high plaque burden but display no symptoms of dementia. As nucleic 
acids are a large component of NETs, this finding could also suggest that the presence of NETs 
around amyloid plaques promotes an inflammatory response from surrounding cells (Figure 
1.3). The same study also found that nucleic acids promoted Aß aggregation (46), which could 





Figure 1.5.1: NET persistence around amyloid plaques may promote chronic inflammation. Neutrophils 
have been seen to migrate towards amyloid plaques in the brain. Furthermore, NETs have been found to form 
around the sites of these plaques. Reduced clearance of the NETs could mean inflammatory signals continue to be 
released at plaque sites, causing further neutrophil recruitment and NET formation. NET formation localises the 
immune response and promotes inflammation; therefore, it may recruit other immune cells such as microglia. Hill, 
2020, original work. 
 
 
Previous studies show strong evidence for a potential interaction between neutrophils and Aβ; 
however, the molecular details of this interaction have not yet been clarified. There is a clear 
gap in the literature that calls for an understanding of how neutrophils may interact with Aβ 
plaques or modify their immunogenicity. The aim of the present study is to clarify the 
discrepancy in the literature around this interaction, and the possible contribution of the 
peripheral immune system to Alzheimer’s disease.  
 
1.6 HYPOTHESES AND AIMS 
The purpose of this study was to further investigate the potential interaction between Aβ and 
NETs and its possibility to contribute to AD pathogenesis. Along with the literature detailed in 
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section 1.5, previous work from our laboratory has found the presence of NET proteins in 
isolated Aβ plaques. Interestingly, their unpublished results also show that in vitro, Aβ alone 
does not cause an immune response in other brain cells, creating questions as to why NETs are 
seen clustered around the Aβ plaques in vivo. Therefore, I hypothesise that NETs could be 
modifiers of Aβ and these potential modifications could cause downstream inflammatory 
effects. The Aβ plaques could also be enabling the persistence of  NETs, which would normally 
be phagocytosed, and this could contribute to chronic inflammation in the AD brain, leading to 
further neurodegeneration.  
 
Figure 1.6.1: Proposed plaque modification by NETs as a potential link to neuroinflammation. Neutrophils 
have been shown to migrate towards amyloid plaques in the brain, and the formation of NETs around these plaques 
has been observed. Smyth et al. (unpublished results) have observed that Aß alone does not initiate an immune 
response in vitro and Jansen et al. found that plaque load does not correlate with neurodegeneration (20). Therefore, 
it is possible the neuroinflammation seen in AD is actually due to modification of the plaques by the NETs. These 
modifications to the Aß could be by oxidative proteins such as MPO and the changes in the plaques could be the 
starting point for the inflammatory response. Research by Volkman et al. supports this theory as MPO deficient 
mouse models had less inflammation than controls that had the same Aß plaque load. Hill, 2020, original work. 
 
Therefore, for this study I aimed to characterise and validate four representative species of 
Aβ42 that would normally be present in an AD brain. Aβ42 was chosen as this is the most 
aggregation prone form of the peptide and currently the most closely associated with AD 
pathogenesis. I also aimed to isolate human neutrophils and induce NETosis. Isolating these 
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two components was key to carrying out the final aim of investigating the potential binding 
interaction. In investigating this interaction, I specifically aimed to: 
1) determine if Aβ42 causes NETosis of neutrophils 
2) investigate the binding interaction between four different species of Aβ42 with NETs 
or NET proteins.  
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Chapter 2:  Methods and Materials 
 
2.1 MATERIALS 
Table 2.1.1: A list of the materials used for the experimental methods outlined in this thesis 
Material Catalog 
Number 
Manufacturer  Location  
Aβ42 Preparation      
Lyophilised Aβ42 peptide H1368 Bachem Switzerland 
1, 1, 1, 3, 3, 3-hexafluoro-2-
propanol (HFIP) 
105228 Sigma  St Louis, MO, 
USA 
Protein  Lobind Eppendorf 
tubes  
0030108116 Eppendorf Hamburg, 
Germany 
Anhydrous DMSO D2650 Sigma  St Louis, MO, 
USA 
Phenol-red free DMEM A1443001 Gibco Waltham, MA, 
USA 




96 well clear bottom NUNC 
plate  
167008 Thermo Fisher Scientific  Denmark  
Costar flat bottom high-
binding plate 
3590 Corning Incorporated NY, USA 
Electron Microscopy     
Carbon-coated copper grids EMSCF300H-
CU 
ProSciTech Australia  
Uranyl acetate solution 10288 BDH Laboratory 
Supplies  
Dorset,UK 
Neutrophil Isolation     
Heparin 2339889 Pfizer Auckland, NZ 
PBS P4417 Sigma St Louis, MO, 
USA 
Dextran 101514 MP Biomedicals  Canada 





Endotoxin-free water SH30529.03 GE Healthcare Life 
Sciences  
Logan, Utah, USA  
NaCl AM9759 Thermo Fisher Scientific Auckland, NZ 
Phenol red-free RPMI  11835-030 Gibco  Waltham, MA, 
USA 
Fetal Bovine Serum 
 
SH30406.02 GE Healthcare Life 
Sciences 
Tauranga, NZ 
Trypan Blue T8154 Sigma Gillingham, UK 
Electrophoresis     
SDS 10607443 Fisher BioReagents Hampton, NH, 
USA 
Precision Plus Protein 
Standards 
161-0394 Bio-Rad Seoul, Korea 
8-16% Mini-PROTEAN 
TGX stain free precast gel 
456-8013 Bio-Rad  Seoul, Korea 
Polyvinylidene difluoride 
membrane 




ECL Select™ Western 
Blotting Detection Reagent   




DNase I 04716728001 Roche Basel, Switzerland 
cOmpleteTM Mini Protease 
Inhibitors  
0469311600 Sigma St Louis, MO, 
USA 
Glycerol 356350 Sigma St Louis, MO, 
USA 
Igepal CA-630 I8896 Sigma St Louis, MO, 
USA 
Cell Death Assay    
SYTOX™ Green Dye S7020 Thermo Fisher Scientific OR, USA 
PMA P1585 Sigma St Louis, MO, 
USA 
NET-Aß42 Binding Assay    
PFA 158127 Sigma St Louis, MO, 
USA 




D9542 Sigma St Louis, MO, 
USA 
Microglia Isolation    
Percoll® P4937 Sigma St Louis, MO, 
USA 
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Antibodies (Clone)    
Rabbit anti-human MPO 
(Polyclonal) 




ab92331 Abcam Cambridge, UK 
Monoclonal Mouse anti-
CD66B (G10F5) 




ab68672 Abcam Cambridge, UK 
Rabbit anti-citrullinated 
histone H3 (Polyclonal) 
ab5103 Abcam Cambridge, UK 
Monoclonal mouse anti-
Aβ42 (4G8) 




ab24111 Abcam Cambridge, UK 
Monoclonal mouse anti-
PU.1 (9G7) 
2258 Cell Signalling Danvers, MA, 
USA 
Goat anti-mouse HRP 
(GAMP) (Polyclonal) 


















A31570 Thermo Fisher Scientific OR, USA 
Miscellaneous     
Methanol UN1230 LabServ Waltham, MA, 
USA 
Ethanol UN1170 LabServ Waltham, MA, 
USA 
HEPES BP310-500 Sigma  NJ, USA 
Bovine Serum Albumin 10091148 Thermo Fisher  Auckland, NZ  
TWEEN® 20 P9416 Sigma St Louis, MO, 
USA 






Phosphate Buffered-Saline (PBS)  
 
Initially, a 10 X stock solution was made using 100 mM Na2HPO4, 27 mM KCl, 1.37 M 
NaCl, 18 mM KH2PO4, with pH adjusted to 6.8. This was diluted 1/10 for the 1 X solution 





0.1% (v/v) Triton-X-100 in 1 X PBS. 
 
 
Top Tank Buffer (Electrophoresis) 
 
A 10 X stock solution was made using 250 mM Tris-base, 1.9 M glycine and 35 mM SDS in 
milliQ water. This was diluted 1/10 in milliQ to make a 1X solution.  
 
 
Bottom Tank Buffer (Electrophoresis) 
 
82.6 mM Tris in milliQ water.  
 
 
Western Blot Transfer Buffer  
 
The 10 X stock solution consisted of 250 mM Tris-base and 1.9 M glycine. To make the 1 X 






Triton X-100 X114 Sigma St Louis, MO, 
USA 
Sodium Azide  S8032 Sigma St Louis, MO, 
USA 




Lysis buffer  
 
20 mM Hepes, 150 mM NaCl, 10% [v/v] glycerol and 0.1% [v/v] Igepal CA630 (Nonidet P-





The initial 10 X stock solution consisted of 0.2 M Tris and 1.4 M NaCl in milliQ, with pH 
adjusted to 6.8. To make 1 X, this was diluted 1/10 with 0.5% Tween™20 and milliQ water. 
 
 
Silver stain solutions 
 
Fix solution: 50 % ethanol and 10 % acetic Acid in milliQ 
Wash solution: 5 % ethanol and 1 % acetic Acid in milliQ  
Sodium-Thiosulfate solution: 0.02 % sodium thiosulfate (w/v) in milliQ 
Silver solution: 0.2 % (w/v) silver nitrate, 0.075 % formaldehyde (w/v) in milliQ 
Developing solution: 6 % sodium carbonate (anhydrous, w/v), 2 % sodium thiosulfate 
solution (v/v), 0.05 % formaldehyde (v/v) in milliQ  
Stop solution: 2 % sodium-EDTA (w/v) in milliQ 
 
 
Binding diluent  
 





1% BSA (w/v) was added to PBS-T with 0.04% thiomersal (w/v). 
 
 
Micrococcal Nuclease Reaction Buffer 
 
0.1 % BSA (w/v) was added to 50 mM tris-HCl, 5 mM CaCl2 and milliQ before the solution 







2.3  METHODS 
2.3.1 Formation of four different Aβ42 species  
Aggregated Aß42 was prepared as described previously (93). To obtain the aggregated form of 
the peptide, sterile autoclaved milliQ water was added to the lyophilised Aβ42 peptide to give 
a final peptide concentration of 500 µM. This was then freeze-thawed three times over several 
days to provide a variable distribution of aggregate sizes. 
Monomeric, oligomeric, and fibrillar Aß42 was prepared as described previously (94). The 
lyophilised Aβ42 peptide was dissolved in 1, 1, 1, 3, 3, 3-hexafluoro-2-propanol (HFIP) to 1 
mM. The tube was vortexed vigorously before being placed in a bath sonicator for 30 minutes 
to fully bring the peptide into solution. The Aβ42 HFIP solution was left to sit at room 
temperature for 30 mins, before being aliquoted into single-use lo-bind Eppendorf tubes (20-
50 µg/tube). The tubes were left to sit overnight in a tissue culture hood to evaporate the HFIP 
and the resulting single-use peptide films were stored at -20 °C until use. 
Before use, the Aβ42 peptide film was brought to room temperature and diluted to 5 mM in 
anhydrous dimethyl sulfoxide (DMSO). The newly formed Aβ42 monomers were sonicated for 
10 mins in a bath sonicator at room temperature. The peptides were then diluted in cold phenol-
red free Dulbecco's modified eagle medium (DMEM) to 100 μM. The resulting monomeric 
Aβ42 was used immediately. To obtain oligomers, the same process was used, however the 
peptides were left to incubate overnight at 4°C. To obtain fibrils, peptides were diluted in 10 




2.3.2 Analysis of Aβ42 species using thioflavin T fluorescence  
Thioflavin T (ThT) was diluted to 20 µM in phosphate buffered saline (PBS). The various Aβ42 
species were diluted to 10 µM with the ThT solution in an 96 well clear bottom NUNC Plate 
(Thermo Fisher, Denmark), before being incubated for at least 2 hours at 37°C. The 
fluorescence of the ThT was read on a Thermo Scientific Varioskan Flash plate reader with an 
excitation of 440 nm and emission of 482 nm. The analysis software used was version 5.0 of 
Thermo Scientific SkanIT™ for microplate readers. 
 
2.3.3 Electron microscopy of Aβ42 species  
Copper grids with 300 meshes coated with formvar/carbon film were floated on a 5 μl drop of 
a 100 µM protein sample and incubated for 60 seconds. Grids were washed once with water, 
and then floated on 5 μl of uranyl acetate solution (2% w/v) for 30 seconds. Micrograph images 
were taken on a Philips CM200 200kV transmission electron microscope equipped with a 
Gatan digital camera. 
 
2.3.4 Validation of an Aβ42 binding assay  
All four Aβ42 species were diluted to 0.02 µg/µL with PBS and added (1 µg/well final) in 
duplicate to a Costar flat bottom high-binding plate (Corning, NY, USA). Using a 2:5 dilution 
factor, the Aβ42 species were further diluted in a series and added to the plate until a final 
concentration of 5.2 x 10-5 µM was reached. Matched Aβ42 vehicles were added to the plate as 
controls for nonspecific binding. The plate was covered with a plastic plate sealer and left 
overnight with agitation at 4 °C. Plates were then spun for 5 minutes at 1000 x g. The 
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supernatant was removed and the wells were washed with PBS. Binding diluent was added for 
an hour at room temperature to block non-specific binding. Wells were washed with PBS before 
mouse anti-4G8 (1:10,000 in binding diluent) primary antibody in binding diluent was added 
to one of the duplicates for each concentration. Binding diluent without any primary antibody 
was used as a control. The plate was left overnight with agitation at 4°C before being spun for 
5 minutes at 1000 x g and washed with PBS. Donkey anti-mouse AlexaFluor 488 secondary 
antibody (1:500 in binding diluent) was added to all wells and incubated for at least 2 hours 
before detection on a Thermo Scientific Varioskan Flash plate reader.  
 
2.3.5 Isolation of neutrophils  
Neutrophil preparations were generated as described previously (95). Ethical approval was 
obtained from the New Zealand Southern Health and Disability Ethics Committee 
URA/06/12/083/AM02. Blood from healthy control donors was collected and added to heparin 
(final concentration 10 U/mL). The heparinised blood was diluted 1/3 with PBS and gently 
mixed by inversion. Dextran (5% in 0.9 M NaCl) was added to a final concentration of 1%. 
Tubes were left to stand for 15 minutes to allow for separation. The upper layer from the dextran 
sedimentation was collected and dispensed into fresh Falcon tubes. Where autologous serum 
was taken, whole blood was collected into a red-top uncoated tube, and allowed to clot for 60 
minutes. The tube was then spun at 2000 x g for 10 minutes, and the serum collected. 
The mixed leukocytes were underlaid with Ficoll before the tubes were spun for 20 minutes at 
1000 x g. The upper plasma layer was aspirated off before the peripheral blood mononuclear 
cell (PBMC) layer at the interface was removed. The remaining Ficoll was aspirated off so only 
the pellet, containing red blood cells and granulocytes, remained in the tube.  
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Each pellet was gently resuspended in 10 mL of PBS. Cell suspensions were then diluted 1/3 
in endotoxin-free water for hypotonic lysis of red blood cells. After exactly 2 minutes, 
suspensions were diluted 3/4 with NaCl (2.7%), and mixed by inversion to restore osmolarity. 
Cells were spun for 5 minutes at 450 x g. Supernatants were aspirated and the neutrophil pellets 
resuspended in phenol red-free RPMI with 2% FBS. Neutrophils from every 10 mL of  normal 
donor blood were resuspended in 1 mL, resulting in concentrations of 1.1-3.5 x 107 
neutrophils/ml. Neutrophil suspensions were counted using a haemocytometer and Trypan blue 
exclusion. Cells were assessed using a Beckman Coulter FC 500 MPL cytometer to determine 
neutrophil purity based on forward and side scatter values. Generally, 10 000 cellular events 
were taken.  
 
2.3.6 Flow cytometry  
Neutrophils and PBMCs in RPMI (2% FBS, 10 mM HEPES) were added to a 96 well round-
bottom NUNC plate at 1 x106 cells/mL. Primary antibodies were added and incubated for 15 
minutes with agitation. The suspension was diluted with media and spun for 5 minutes at 450 
x g. The media was aspirated off the top of the wells before the cells were resuspended in the 
same media. FITC fluorescence forward scatter and side scatter was analysed on a Beckman 
Coulter FC 500 MPL cytometer. Flowing software (version 2.5.1) was used to analyse 
proportions of each cell type. FlowJo (version 10.7.1) was used to generate representative 




Table 2.3.1: Antibodies used for flow cytometry 
















555412 BD Biosciences NJ, USA 
 
 
2.3.7 Electrophoresis and western blotting   
Lysis buffer supplemented with protease inhibitors was added to 5 x 106 neutrophils. Cells were 
incubated on ice for 30 minutes with agitation before centrifugation at 14,000 × g for 10 min at 
4 °C. This generated a clarified neutrophil lysate. Conditioned media was harvested from 
unstimulated and PMA-stimulated neutrophils in RPMI with no additives, and spun at 1000 x 
g to remove any contaminating neutrophils. Digested NETs were prepared following 4 h of 
PMA (20 nM) stimulation using deoxyribonuclease (DNase) (10 U/mL, 5 min, 37 oC). Samples 
were stored at -20 oC until further use. 
Neutrophil lysate (10 μg), conditioned media, PMA conditioned media and digested NETs were 
loaded for electrophoresis on a 8-16% polyacrylamide gel. Solutions were separated using 
polyacrylamide gel electrophoresis as described previously (96). The gel was fixed for 30 
minutes, at room temperature, with agitation. The fixative was discarded and the gel washed 
with wash solution for 15 minutes with agitation. MilliQ water was used to wash the gel before 
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the addition of sodium thiosulfate solution. After 2 minutes the gel was washed again with 
milliQ water. Silver solution was added for 30 minutes before the gel was washed 3 times more. 
Developing solution was added and discarded once strong bands started to appear. Stop solution 
was added for 10 minutes to halt the development of the gel.  
A second gel containing the same samples was transferred to a PVDF membrane. The 
membrane was blocked with 5% BSA in TBS-T for one hour before the addition of the primary 
antibody, which was left to incubate overnight at 4 ºC. The membrane was washed 3 times with 
TBS-T before the horseradish peroxidase conjugated secondary antibody was added. This was 
incubated for at least 2 hours at room temperature before analysis. The enhanced 
chemiluminescence (ECL) system was used to detect the secondary-antibody. Primary 
antibodies were made up in 1 % BSA and 0.02 % azide in TBS-T. The azide was omitted for 
secondary antibodies.  
 
Table 2.3.2: Antibodies used for western blotting 
























2.3.8 SYTOX™ green assay to measure NETosis 
Neutrophils were diluted to 1 x 106 cells/mL before SYTOX™ green was added to a final 
concentration of 10 µM. This stock solution was then used to make preparations containing 
either 10% serum from the same donor of the neutrophils or mouse anti-4G8 antibody 
(1:10000). Aβ42 monomers, oligomers, fibrils, aggregates, and their corresponding vehicles 
were prepared according to section 2.3.1. Each species was added to the neutrophils only, serum 
and antibody preparations to give a final concentration of 5 µM Aß42. PMA (20 nM) was added 
to the neutrophils as a positive control. Untreated cells were added to the plate to be used as a 
background measurement. The SYTOX™ green fluorescence was measured on a BioTek 
Synergy Neo2 Multi-Mode plate reader at 5 minute intervals for a period of 5 hours using the 
GFP filter cube (excitation 470/35, emission 525/40). The blank cell measurements and 
background SYTOX™ green signal were subtracted from the data before statistical analysis.  
 
2.3.9 Initial Aβ42-NET binding assay  
For each Aβ42 species, 0.1 µg/well was added to a Costar 3590 flat bottom high-binding plate 
before incubation overnight at 4 °C. Vehicles were added as controls. The plate was prepared 
according to section 2.3.4. Previously prepared digested NETs were diluted 100 x and added to 
half the plate. Diluted RPMI media was used as a control. NETs were incubated with Aβ42 for 
at least an hour before the plate was washed with PBS. Primary antibodies (in binding diluent) 
against various NET proteins were detected using corresponding Alexa Fluor-488 secondary 
antibodies. Secondary antibody fluorescence was detected on a Thermo Scientific Varioskan 




2.3.10 Immunocytochemistry and formation of NET-lawn plates 
Neutrophils were diluted to 1 x 106 cells/mL and added to 96 well NUNC plates before being 
treated with PMA (20 nM final concentration) to induce NET formation. After 4 hours 
incubation at 37 °C, half of the cells were treated with micrococcal nuclease (MNase) to digest 
extracellular DNA. Wells were washed before Aβ42 species in phenol-free DMEM were added 
to the plate to a concentration of 2.5 µM. Vehicle and untreated controls were included. After 
1 hour incubation at 37 °C, 8% PFA was added at a 1:1 ratio to media for fixation. After 15-20 
minutes at room temperature, the wells were washed 3 times with PBS-T to permeabilise and 
remove PFA. Mouse anti-4G8 primary antibody in immunobuffer was added to the plate and 
incubated overnight at 4°C. The primary was removed and the plate was washed 2-3 times in 
PBS-T before appropriate species-specific fluorescent secondary antibodies and 4′, 6-
diamidino-2-phenylindole (DAPI; 500 nM, in immunobuffer) were added. The plate was left 
for at least 2 hours with no light, at room temperature, before wells were washed with PBS-T 
and imaged. 
Images of 9 sites per well (3 x 3) at 10X objective were acquired in DAPI (Ex 377/25, Em 
447/30), FITC (Ex 482/15, Em 533/20), and CY3 (Ex 533/20, Em 590/20) fluorescence filters 
on an Olympus IX81 microscope. Aß42 staining was quantified using a custom pipeline 
developed in CellProfiler (version 3.5.1). Initially, bright staining in the background channel 
was used to mask staining in the Aß42 (FITC) channel. Bright Aß42 staining was then 




Figure 2.3.1: CellProfiler quantitative analysis process. (a) Original fluorescent image of Aß42 fibrils and 
NETs. (b) Identification of autofluorescence. (c) Expansion of autofluorescence to get a thresholded area. (d) 
Masking of the Aß42 (FITC) channel. (e) Identification of bright Aß42 staining used for quantification. 
 
2.3.11 Addition of NETs and Aβ42 to microglia  
Primary cultures of microglia were obtained from wild-type C57/Bl6 mice as described 
previously (97). Briefly, mouse brains were mechanically and enzymatically dissociated before 
vessel depletion in 10% dextran in PBS. The vessel depleted brain was brought to 30% percoll 
concentration and overlaid on a 70% percoll solution. The suspension was spun at 1000 x g for 
10 minutes. The myelin debris layer was removed and the interface collected and plated into a 
96 well plate in DMEM supplemented with 10% FBS for 7 days until microglia had extended 
processes. Staining for the microglial transcription factor PU.1 revealed cultures were over 90% 
pure. The four species of Aβ42 (1 μM) and previously prepared digested NETs (10 μg/mL) 
were added to the microglia and incubated overnight at 37 °C. The plate was fixed and imaged 
according to section 2.3.10.  
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2.3.12 Statistical analysis  
Graphs were created on GraphPad Prism, version 8.0.2 (GraphPad Software, La Jolla, 
California, USA). The appropriate statistics for each result were performed on this software.  
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Chapter 3: Results  
 
3.1 VALIDATION AND CHARACTERISATION OF Aß42 SPECIES 
3.1.1 Thioflavin T fluorescence indicated the presence of different species of Aß42  
As Aß42 is incredibly prone to aggregation (12–14), it does not have a stable structure and can 
exist in many aggregation states in the brain. Monomeric, oligomeric and fibrillar Aß are all 
present, along with senile plaques, in the AD brain environment. Therefore, when studying Aß 
interactions with neutrophils, it is important to represent all of these different species 
experimentally.  
Aggregated Aß42 sediments rapidly and can be seen as white precipitate. However, when 
preparing the other Aß42 species, there are no visual clues that enable the determination that 
the desired products have formed. Thioflavin T (ThT) is a benzothiazole dye that exhibits a 
fluorescent signal when it binds to ß-sheet structures. Due to the ability of Aß peptides to 
aggregate together to form ß-sheets, ThT was established early on as a suitable compound for 
measuring Aß aggregation (98). ThT consists of a benzylamine and a benzathiole ring which 
can rotate freely through a carbon-carbon bond (Figure 3.1.1) (99, 100). When ThT binds to ß-
sheets, the ring movement is inhibited, causing the dye to remain in a configuration that 
enhances fluorescence (100). Therefore, the more ß-sheets and aggregated peptide present in 





Figure 3.1.1: Chemical structure of thioflavin T 
ThT (20 µM) was added to the monomeric, oligomeric, fibrillar and aggregated Aß42 to give 
an indication of the amount of structure in the preparations. An average of the background ThT 
fluorescence, measured by ThT addition to PBS alone, was subtracted from all values to derive 
true fluorescence for each species.  
 
Figure 3.1.2: Analysis of Aβ42 species using thioflavin T. Aβ42 species were prepared as described in section 
2.3.1. Aß42 species (10 μM) were added to ThT (20 µM) and fluorescence (Ex 455/Em 482) was measured. Data 
are presented as arbitrary fluorescent units on a log scale to show dynamic range. Each point on the graph 
represents the mean of 3 technical replicates from independent preparations. Error bars represent the mean ± SEM 
of 7 experimental replicates. A one-way ANOVA with a Tukey’s multiple comparison test was used to determine 
if the differences between species were significant (p<0.05). The aggregated Aß42 was significantly different to 
monomers, oligomers and fibrils (**** p <0.0001, *** p <0.001).  
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All Aß42 species showed variability between replicates; however, fibrillar and aggregated 
Aß42 still consistently had 2-10 fold higher ThT fluorescence than oligomeric and monomeric 
species (Figure 3.1.2). ThT fluorescence in aggregated Aß42 samples was significantly higher 
than in monomer and oligomer samples (p < 0.001), whereas fibrillar Aß42 was not 
significantly higher than either of the smaller species. On average, the aggregated Aß42 also 
had significantly higher ThT fluorescence than the fibrils (p = 0.008). Although Aß fibril 
difference was nonsignificant, these results still imply that the fibril and aggregate preparations 
contained more ß-sheet structure than the smaller species preparations. Therefore, this assay 
indicated the formation of the four desired different species of Aß42. 
 
3.1.2 Electron microscopy confirmed four different Aß42 species  
Visualisation was required to ensure fibrillar and aggregated structures were present in the 
preparations. Electron microscopy has previously been used to observe the structures of Aß 
species (101). To further validate the Aß42 species fidelity; monomeric, oligomeric, fibrillar, 
and aggregated samples were prepared and observed by electron microscopy after negative 




Figure 3.1.3: Representative images of Aß42 species visualized by electron microscopy. Aβ42 species were 
prepared as described in section 2.3.3. Scale bar = 100 μm.  
 
Electron microscopy confirmed that all four species of Aß42 were being successfully formed. 
As expected, the monomeric preparation showed mainly grainy background as Aβ42 monomers 
are too small to image with electron microscopy (Figure 3.1.3). In the oligomeric preparation, 
clusters of bead-like oligomeric Aß42 were observed (Figure 3.1.3). In the fibril preparation, 
clear rope-like structures typical of Aß fibrils were present, and large macro-aggregates were 
observed in the aggregate preparation (Figure 3.1.3). Overall, aggregates were substantially 





3.2 ISOLATING NEUTROPHILS AND FORMING NETs 
3.2.1 Flow cytometry determined high neutrophil purity  
Neutrophils and PBMCs were isolated according to section 2.3.5, and the purity of the 
preparations was assessed using flow cytometry. Antibodies against typical neutrophil 
(CD66b), monocyte (CD33), T cell (CD3), and B cell (CD19) lineage markers were used to 
further assess purity. The presence of these cell surface markers in isolated neutrophil and 
PBMC preparations were detected using monoclonal antibodies listed in table 2.3.1. It was 
expected that isolated neutrophils would express CD66b only, and the PBMC populations 




Figure 3.2.1: Flow cytometry to determine purity of isolated neutrophils. Unstained isolated neutrophils and 
PBMCs were analysed by flow cytometry. (a) Representative scatterplot of forward and side scatter with gating 
of lymphocyte, monocyte and neutrophil populations. (b) Quantification of percentage of neutrophil, monocyte, 
and lymphocyte cells present within isolated neutrophils and PBMCs. Error bars represent the mean ± SEM of 12 
replicates. A 2-way ANOVA with a Tukey’s multiple comparison test was used to determine if the differences 
between groups were significant (p < 0.05). Differences between neutrophils and PBMCs for all groups were 
statistically significant with p values < 0.0001. Isolated neutrophils and PBMCs were stained with lineage markers 
and analysed by flow cytometry. (c) Representative histograms of the FITC fluorescence of antibodies against 
lineage markers CD66b, CD33, CD3 and CD19 in neutrophil and PBMC populations. (d) Quantification of the 
proportion of CD66b, CD33, CD3, and CD19 within isolated neutrophils and PBMCs. Error bars represent the 
mean ± SEM of three individual replicates. A 2-way ANOVA with a Tukey’s multiple comparison test determined 
there were statistically significant differences between neutrophils and PBMCS for CD66b and CD3 (p < 0.0001). 
 
Neutrophil preparations carried out during the course of this study had high purity (average 
purity 92%, Figure 3.2.1, a, b) with few contaminating PBMCs. Antibodies were also used to 
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stain neutrophils and PBMCs to provide a more robust analysis of purity. Neutrophil 
preparations showed high levels of positive cells for CD66b and low levels for CD33, CD3, 
CD19 (Figure 3.2.1 c, d), further supporting that preparations were of high purity.  
 
3.2.2 Successful induction of NETosis using PMA 
The discovery of NETs by Brinkman et al. introduced the use of phorbol 12-myristate 13-
acetate (PMA) as an inducer of NETosis (62). PMA can quickly and effectively stimulate 
NETosis by activating phosphokinase C and triggering downstream ROS production in 
neutrophils (102). PMA (20 nM) was used to induce NETosis in neutrophils after isolation. 
PMA-treated neutrophils were used for generation of NETs en masse, and as positive controls 
to determine what NETosis looks like experimentally. This control was necessary for 





Figure 3.2.2: Neutrophil response over time after PMA treatment. PMA (20 nM) was added to isolated 
neutrophils before incubation at 37 ºC for 4 hours. Cells were observed under a microscope and images were taken 
at 10, 30, 60, 120, 180 and 240 minute increments at 20X objective. Scale = 100 µM 
 
Neutrophils quickly began to undergo cell death after treatment with PMA (Figure 3.2.2). 
Neutrophils progressed from round, phase-bright cells to adherent, multi-lobed cells within 30 
minutes of PMA exposure (Figure 3.2.2). After 4 hours, lytic morphology was observed for the 
majority of the cells, indicating cell death. These observations are consistent with NET 
formation, however do not confirm that the cell death occurring is not through other 
mechanisms such as apoptosis or necrosis.   
The formation of NETs was quantitatively assessed using a SYTOX™ green cell death assay. 
SYTOX™ green is a fluorescent membrane-impermeable DNA-binding dye that has 
previously been established to effectively measure NETosis (103). The dye exhibits a 500-fold 
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increase in fluorescence when bound to nucleic acids (103). Since it is unable to cross cell 
membranes, fluorescence will only increase when cell membrane integrity is lost, as is the case 
in NETosis. SYTOX™ green was added to isolated neutrophil populations treated with PMA 
and fluorescence was read over time to measure the rate of NETosis.  
 
Figure 3.2.3: Treatment with PMA induced cell death in isolated neutrophils. The SYTOX™ green 
fluorescence of untreated neutrophils, neutrophils treated with vehicle (0.003% DMSO), or PMA (20 nM) was 
measured every ten minutes for five hours. (a) Representative graph of experiment measuring SYTOX™ green 
fluorescence over time in PMA-treated neutrophils. Each point on the graph represents the mean ± SEM of three 
technical replicates. (b) Quantification of the extent of cell death induced by PMA, as arbitrary fluorescent units 
(AFU). Each point on the graph represents the mean maximum SYTOX™ green fluorescence value after 300 
minutes for three technical replicates from an independent preparation.  Error bars on the graph represent the mean 
± SEM of 7 experimental replicates. An ordinary one-way ANOVA with a Tukey’s multiple comparison test was 
used to determine if the differences in cell death between the PMA-treated neutrophils and controls were 
significant (p < 0.05). The PMA condition was both significantly different to the untreated and vehicle conditions 
with p values for both < 0.001.  
 
The maximum SYTOX™ green fluorescence in neutrophils treated with PMA was significantly 
higher than untreated (p = 0.0007) or vehicle (p = 0.0003) neutrophil conditions. Untreated and 
vehicle conditions consistently had a maximum fluorescence of less than half of the PMA 
treated neutrophils after 5 hours (Figure 3.2.3 a, b), indicating the upper and lower bounds of 
this assay. This implies that neutrophil membrane integrity was compromised, and indicated 
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that DNA was being released by neutrophils. However, the assay again could not confirm that 
NETosis was occurring. Interestingly, SYTOX™ green fluorescence increased dramatically 
between 80 and 150 minutes post-PMA stimulation, indicating that this is the critical period for 
possible NETosis execution (Figure 3.2.3 a). On the other hand, the untreated and vehicle 
conditions had relatively stable fluorescence (Figure 3.2.3 a).   
 
3.2.3 Characterisation of NETs by identification of their protein components  
To visually confirm the cell death observed (Figure 3.2.2, 3.2.3) was indeed NETosis, 
fluorescent images of PMA treated neutrophils stained with the DNA-intercalating dye, DAPI, 
were acquired on an Olympus IX81 microscope. 
 
Figure 3.2.4: Isolated neutrophils treated with PMA undergo NETosis. Differential interference contrast 
(DIC) image of NETs. Neutrophils were treated with PMA for 4 hours before being fixed, stained and imaged 
according to section 2.3.10. Bright spots show multilobed intact nuclei that have not undergone NETosis. More 
dull spots show former neutrophil nuclei that have undergone NETosis. Arrows indicate stretches of extracellular 
DNA released by neutrophils as a response to PMA treatment. Magnification is 20 X.  
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All PMA-treated wells showed clear NET morphology with long fibres extending from 
neutrophil nuclei, stained with DAPI (blue) (Figure 3.2.4). Cell membrane structure had clearly 
been compromised and DAPI stained DNA was seen to stretch out of the burst cells (Figure 
3.2.4). 
To further confirm that the cell death observed after addition of PMA to neutrophils was in fact 
NETosis, DNase digested samples of the neutrophils after PMA incubation were analysed by 
silver stain and western blot for NET markers. Neutrophil lysate and conditioned media samples 
were used as positive and negative controls. Western blot was utilised to determine if the 
digested samples contained typical NET proteins, and that proteins not present in NETs were 
absent.  
Primary antibodies against CD66b, MPO and S100A8 were added to the membranes to 
determine the presence or absence of NETs. As CD66b is a neutrophil surface receptor, it was 
expected to be abundant in the neutrophil lysate. If NETs had formed after PMA treatment, 
neutrophil membranes would no longer be intact, and so it was expected that CD66b would not 
be present in the digested NETs. Conditioned media from PMA stimulated cells was used to 
ensure that the proteins detected were associated with NET complexes, rather than being 
secreted during degranulation. As discussed previously in section 1.4.2, MPO is abundant in 
neutrophils (62, 104), and critical for NET formation (67). Therefore it would be expected to 
be present in neutrophil lysate and digested NETs. S100A8 is a subunit of a heterodimer, 




Figure 3.2.5: Digested NETs expressed typical NET proteins, MPO and S100A8, and did not express 
neutrophil surface protein CD66b. NETs, neutrophil lysate, or conditioned media from PMA-stimulated 
neutrophils were analysed by silver staining and western blotting. (a) Visual protocol for obtaining conditioned 
media and digested NET samples analysed by electrophoresis. Hill, 2020, original work. (b) Silver stain of proteins 
in neutrophil lysate, conditioned media, and digested NETs. The corresponding ladder indicates relative molecular 
weight. (c) Western blots against CD66b, MPO and S100A8. * signals non-specific bands (d) Intensities, 
represented as a percentage of the neutrophil lysate, of the bands present in the conditioned media and digested 
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NET samples. Error bars represent the mean ± SEM of three technical replicates from independent preparations. 
An unpaired t test was used to determine if there were significant differences between the intensity of the 
conditioned media samples in comparison to the digested NETs. Statistically significant differences were observed 
for MPO and S100A8, with both having p values of 0.0015.  
 
Silver staining revealed different banding patterns when comparing the neutrophil lysate and 
NET samples. The first western blot against CD66b showed this protein was present in the 
neutrophil lysate only, and not in the conditioned media or digested NET samples (Figure 3.2.5, 
b). MPO was found to be present in the neutrophil lysate and the digested NET samples (Figure 
3.2.5, b). No MPO was detected in the conditioned media samples, suggesting that it is present 
solely on the NETs and is not released during neutrophil degranulation.  S100A8 was detected 
in all of the samples; however, the bands for the digested NET samples were stronger than the 
neutrophil lysate and conditioned media samples (Figure 3.2.5, b). This suggests that S100A8 
is in complex with NETs, as observed previously (104). 
There is significantly higher abundance of MPO and S100A8 present in digested NET samples 
in comparison to conditioned media samples (p = 0.0015), and CD66b is absent (Figure 3.2.5, 
c). The presence of these NET markers, in the absence of any cellular markers indicated that 
NETosis had occurred, and that NET suspensions could successfully be generated. The 
validation of these samples was important for later experiments, as the digested NET mixtures 
were used in the investigation of Aß42-NET binding using the assay described in section 2.3.9 




3.3 NET AB BINDING INTERACTION  
3.3.1 Aß42 does not cause NETosis 
Zenaro et al. observed the formation of NETs around Aß plaques in mouse models of AD by 
visualising the migration of neutrophils into the brain parenchyma and colocalization of 
citrullinated histone H3 and MPO around plaque sites (39). The present study therefore 
hypothesised that Aß42 was the trigger for plaque-associated NETosis.  
A similar SYTOX™ green assay as in section 3.2.2 was used to assess NETosis when Aß42 
species were added to isolated human neutrophils. SYTOX™ green fluorescence was measured 
over time in neutrophils exposed to Aß42 monomers, oligomers, fibrils and aggregates. It was 
important to consider that in the AD brain environment, plaques are associated with Aß42 in 
many aggregation states as well as other immunogenic factors, and so the peptide itself may 
not be sufficient to induce an immune response.  
One source of plaque-associated immunogens is BBB leakage, which occurs in AD (33, 34, 
59). It was hypothesised that non-specific antibodies binding to ‘sticky’ Aß plaques may cause 
the an off-target immune response against plaques. Antibody binding to Aβ42 could potentially 
enable neutrophil recognition of Aß42 and promote NETosis. To test the impact of non-specific 
antibody-Aβ42 binding on NETosis, 10% autologous donor serum was added to the neutrophil-
Aß42 mixtures. Furthermore, specific antibody binding to Aß may be needed to elicit NETosis, 
and so a monoclonal anti-Aß antibody, 4G8, was used to identify the impact of specific 







Figure 3.3.1: Aß42 does not cause NETosis, irrespective of aggregation state or presence of antibodies. (a) 
Representative SYTOX green assay measuring NETosis after addition of Aß42 species. Aß42 was either added to 
neutrophils alone, or supplemented with serum or anti-Aß 4G8. To avoid complication, the four different Aß42 
species are colorised together in normal, serum and 4G8 groups. PMA was added to neutrophils as a positive 
control. Each point on the graph represents the mean ± SEM of three technical replicates from independent 
preparations. N=4. (b) Quantification of the extent of NETosis after Aß42 addition, as arbitrary fluorescent units 
(AFU). Each point on the graph represents the mean maximum SYTOX™ green fluorescence value after 300 
minutes for two technical replicates from independent preparations. Error bars represent the mean ± SEM of four 
replicates. A 2-way ANOVA with a Tukey’s multiple comparison test determined that there were no significant 
differences between any of the groups.  
 
The SYTOX™ green fluorescence remained at vehicle level for all conditions except PMA 
treated neutrophils (Figure 3.3.1 a, b). Although NETosis is unlikely to be occurring in the 
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vehicle condition, fluorescence increases. This is probably due to the fact there is constitutive 
cell death in neutrophils over five hours. All other conditions in the assay have values that 
match or are below these baseline cell death values, suggesting that none are promoting NET 
formation.  
For all Aß42 species, regardless of supplementation with serum or the 4G8 antibody, the 
maximum SYTOX™ green fluorescence after 5 hours was similar to that of the vehicle 
condition (Figure 3.3.1, b). Most of the species had similar maximum fluorescence values as 
the background, suggesting that little NETosis had occurred. There was some variation in the 
aggregated Aß42 condition, particularly when supplemented with serum. This was due to one 
particular donor who had maximum fluorescence values in between the PMA positive control 
and the vehicle, suggesting that some NETosis had occurred in this particular individuals 
neutrophils. 
 
3.3.2 Validation of a potential binding assay using immobilised Aß42  
As one of the main aims of this thesis was to further characterise the interaction between Aß42 
and NETs, there was a need to develop an assay that could effectively measure the binding 
between the two. Initially, an enzyme-linked immunosorbent assay (ELISA) strategy was used, 
where Aß42 was immobilised at various concentrations to the bottom of a high-bind plate and 
detected with an anti-Aß primary antibody, 4G8, to ensure that Aβ had been successfully 
immobilised. The vehicle fluorescence value was subtracted from the experimental 




Figure 3.3.2: Conceptional design for immobilisation of Aß42 and Aß42-NET binding assay. (a) Proposed 
detection method of Aß42 species. Aß42 species were serially diluted (0.3 pg/well - 1 µg/well) and added to high-
bind plates. This was followed with the addition of a monoclonal primary antibody against Aß, 4G8. A fluorescent 
secondary antibody, alexa-fluor 488, was added for primary detection so Aβ42 abundance could be quantified. (b) 
Proposed mechanism of measuring Aß42-NET binding. Aß42 species were bound to high-bind plates before 
incubation with previously prepared digested NETs (section 2.3.7). It was hypothesized components of the NETs, 
such as DNA or proteins would bind to the immobilized Aß42. The amount of NET binding was detected by a 
primary anti-MPO antibody and alexa-fluor 488. Hill, 2020, original work. 
 
Figure 3.3.3: Validation of a potential assay to measure Aß42 binding interactions with NETs. Aß42 species 
were serially diluted (0.3 pg/well - 1 µg/well) and added to high-bind plates. Fluorescence intensity was measured 
on a plate reader and Aβ42 abundance quantified by 4G8 signal intensity. Each point on the graph represents the 
mean ± SEM of two technical replicates from an independent preparation. Data are presented on a log scale to 
show dynamic range.  
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These data indicated that Aβ42 was successfully immobilised to high-bind plates, and that 
NETs or NET proteins could be added to these plates to define binding. The high-binding plates 
effectively bound all forms of the Aß42. Binding was saturated at a concentration of 0.05 µg 
per well for all Aß42 species, and this concentration was used to coat plates going forward. 
 
3.3.3 Troubleshooting of the initial NET-Aß42 binding assay 
Formation of a successful assay to measure binding required a significant amount of 
troubleshooting. The immobilised Aß42 plate detailed in section 3.3.2 initially seemed like it 
would effectively measure binding between NETs and Aß42, as Aβ42 was successfully 
immobilised and there was good signal to noise ratio. Digested NET samples characterised in 
section 3.2.3 were added to the immobilised Aß42 plates, and incubated at room temperature 
for a period of time, before being washed and detected with primary and secondary antibodies. 
The NET component MPO was chosen for detection in wells due to its abundance in NETs and 
strong and specific labelling by immunoblotting. 
In the first replicate of this assay, using a 1:50 dilution of the digested NET samples, there was 
higher fluorescence intensity in wells that the anti-MPO primary antibody had been added to in 
comparison to wells with no primary. However, the difference between wells that contained 




Figure 3.3.4: MPO from digested NETs binds to both BSA-coated and Aβ42 coated wells equally. NETs 
were diluted 1:50 before addition to the Aß42 plate and a 24 hour incubation. MPO staining was then quantified 
using immunofluorescence and detected using a plate reader. Fluorescence measurements shown are of Aβ42 
species, or their corresponding vehicles, incubated with or without NETs. Statistics were not able to be performed 
as N = 1.   
 
Aß42 fluorescence was only slightly higher than that of the vehicle samples in the initial 
experiment (Figure 3.3.4). This suggests there was still a significant amount of MPO binding, 
and therefore primary antibody binding, in wells that did not contain any Aß42. It seemed the 
MPO signal was saturated, indicating potentially too much NET adherence to the wells, even 
in the absence of Aß42 (Figure 3.3.4). It was hypothesised that nonspecific binding may have 
been enhanced by a long incubation of high concentrations of NETs with the plate, saturating 
specific binding. Therefore, the NETs were further diluted, and the amount of time they were 
incubated on the plate before washing was decreased.  
Even though multiple variations of dilution and incubation times were trialled, there was little 
success in obtaining meaningful results. Figure 3.3.5 shows the summarised results of further 
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assays where a 1:100 dilution of the digested NETs was used and the incubation time was 
shorted to 1-3 hours.  
 
Figure 3.3.5: Reduced NET concentration and incubation time do not enhance the specific binding of MPO 
to Aβ42. NETs were incubated for 1-3 hours on the immobilised Aß42 plate. MPO staining was then quantified 
using immunofluorescence and detected using a plate reader. Fluorescence measurements shown are of Aβ42 
species, or their corresponding vehicles, incubated with or without NETs. Each point on the graph represents the 
mean of three technical replicates from an independent preparation. Error bars on the graph represent the mean ± 
SEM of three individual replicates. A 2-way ANOVA with a Tukey’s multiple comparison test determined that 
there were no significant differences between any of the groups. N=3 
 
Varied dilution and incubation methods did not enable the observation of more specific binding 
and the vehicle fluorescence values remained similar to the Aß42 values. As well as this, there 
was no longer a significant difference between the fluorescence measured in wells with primary 
antibody added and wells with no primary antibody. Due to the limited time frame of the study 
and the consistent negative results, an alternate method was developed to measure Aß42 and 




3.3.4 Aggregated Aß42 species binding to NETs is potentially mediated by the NET 
DNA matrix  
Due to the immobilised Aß42 assay being unsuccessful, a new approach was undertaken where 
NETs were instead immobilised to 96 well plates. The various Aß42 species were added to 
these ‘NET lawns’ to investigate the potential binding interaction. To generate NET lawns, 
neutrophils were treated with PMA for 4 hours to allow NETosis to proceed to completion. 
Cells were observed under a microscope to confirm the formation of NETs. The neutrophils 
had clearly lost their round shape and membrane structure, displaying morphologies observed 
in figure 3.2.2. After addition of Aß42 and fixation with PFA, the plates were again observed 
under the microscope to ensure NETs were still present. Aß42 species were also added to 
uncoated wells to ensure that any binding observed was between NETs and Aß42 (not shown), 
as the properties of Aß make it prone to binding to plastic (105).   
 
Figure 3.3.6: All Aß42 species are deposited in NET lawns. Aβ42 species were added to NET lawns before 
plates were fixed and immunostained for Aβ42. Representative images are shown of immunostaining for NET 
DNA matrix (DAPI; blue), and Aß42 (4G8; green), as well as autofluorescence (magenta). (a) Background images 
showing autofluorescence (b) Images showing extent of Aß42 binding for all species. Arrows highlight specific 




Imaging with a fluorescent microscope showed clear colocalisation of the NETs and Aß42 
(Figure 3.3.6). Minimal amounts of Aß42 were found present in the wells not containing NETs, 
signalling that the Aß42 was not binding to the plastic plate. All four species of Aß42 were 
found to specifically be located in areas with NETs in comparison to regions where the NET 
lawn had been sloughed off. The Aß42 species (green) can be seen surrounding or overlaying 
areas of densely packed NETs (blue). When imaging the initial experiments, a high level of 
autofluorescence was observed (Figure 3.3.6, a). To combat this, a third channel, Cy3, was 
imaged to detect autofluorescence without additional stains, alongside the FITC and DAPI 
channels. This background was subtracted from the Aß42 images during quantification, 
ensuring non-specific fluorescence that was not from Aß42 was not included in the results. 
To further investigate the specifics of the binding interaction observed in figure 3.3.6, 
micrococcal nuclease (MNase) was used to digest the NET DNA before addition of the Aß42 
species. MNase is a DNA degrading enzyme that can quickly break down the extended DNA 
structures released by the NETs, leaving only the globular protein domains. The aim was to 





Figure 3.3.7: The binding interaction of NETs and aggregated Aß42 is reduced after MNase treatment. 
Aβ42 was added to NET lawns treated with MNase before plates were fixed and immunostained for Aβ42. 
Representative images are shown of immunostaining for NET DNA matrix (DAPI; blue), and Aß42 (4G8; green) 
as well as autofluorescence (magenta). (a) Background images showing autofluorescence (b) Images showing 
extent of Aß42 binding for all species. Arrows highlight specific (ie. Autofluorescence-negative) Aβ42 staining. 
Scale = 50 µM. N=5 
 
The fluorescent images of the MNase digested NETs (Figure 3.3.7) show striking differences 
to previous images containing the untreated NETs (Figure 3.3.6). The long extracellular DNA 
fibres observed by DAPI staining were no longer present. While there is little presence of 
fibrillar and aggregated species, deposition of Aß42 monomeric and oligomeric species can still 
be observed. The monomeric Aß42 was most prominent, but unlike the distribution in the 
presence of NETs, the peptide was instead observed in small rings throughout MNase treated 
wells (Figure 3.3.7).  
From a visual perspective, the fibrillar Aß42 was the species with the most striking difference 
between the untreated NETs and MNase treated NETs. In all initial experimental replicates, 
large fibrillar structures were observed colocalised with areas densely packed with NETs. 
However, fibrillar Aß42 structures appeared to be absent from the majority of the wells when 
added to MNase treated NETs. The aggregated Aß42 behaved similarly to the fibril condition, 
 
59 
showing that when wells are treated with MNase, the more aggregated species seem to have 
less interaction with the NETs.  
The area and intensity of Aß42 across 5 replicates was quantified using CellProfiler to 
determine if there were significant differences between binding to ‘NET lawns’ and MNase 
treated plates. Initially, bright staining in the background channel was used to mask staining in 
the Aß42 (FITC) channel. Bright Aß42 staining was then thresholded, and the area and intensity 
quantified (Section 2.3.10). 
 
Figure 3.3.8: Binding of aggregated Aβ42 to NETs is blunted by digestion of the DNA matrix. Quantification 
of NET lawn - Aß42 binding assays, comparing the amount of Aß42 present in wells with NETs to MNase treated 
NETs. (a) Intensity of pixels relating to Aβ42 fluorescence, represented as a percentage of the vehicle fluorescence 
intensity. Each point on the graph represents the mean of four technical replicates from an independent preparation. 
Error bars represent the mean ± SEM of five individual replicates from separate donors. A 2-way ANOVA with a 
Tukey’s multiple comparison test determined there were no significant differences between the intensity of Aβ42 
present in wells with NETs or wells with MNase treated NETs. (b) Percentage of image area taken up by Aβ42 
fluorescence. Each point on the graph represents the mean of four technical replicates from an independent 
preparation. Error bars represent the mean ± SEM of five individual replicates from separate donors. A 2-way 
ANOVA with a Tukey’s multiple comparison test determined there were no significant differences between the 
area of Aβ42 covering wells with NETs or wells with MNase treated NETs. 
 
The quantitative analysis agrees with visual observations that the more aggregated Aß42 
species seem to interact with the DNA component of the NETs, and when this is taken away 
there is less deposition. However, differences between the intensity and area of Aß42 in 
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untreated NET wells compared to MNase treated wells did not reach significance. Uncoated 
wells had minimal Aß42 staining, suggesting that the interaction seen is actually with the NETs 
and not the plastic plate. When treated with MNase, the intensity and area of the Aß42 drops, 
however this difference is much more pronounced in the more aggregated species.  
 
3.3.5 Microglia phagocytose NETs and Aß42 
Microglia are the resident macrophages of the brain, and have been shown to cluster around Aß 
plaques (44, 45). As microglia contribute to the significant neuroinflammation seen in the AD 
brain, it was decided to investigate the potential effects of NETs and Aß42 on these immune 
cells. Digested NETs (used in section 3.2.3 and 3.3.2) and the Aß42 species were added to 
cultured microglia derived from mouse brains and incubated overnight. NETs were detected 
with an anti-MPO primary antibody and Aß42 species with the 4G8 anti-Aß antibody.  
 
Figure 3.3.9: Microglia phagocytose NETs and all Aß42 species. Representative images showing the addition 
of digested NETs and Aß42 species to microglia cells derived from mouse brains which were then fixed and 
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immunostained for Aβ42. (a, b) Immunostaining for microglia nuclei (DAPI; blue), and Aß42 (4G8; green) as 
well as NETs (MPO; magenta) after NET addition. (c) Immunostaining for microglia nuclei (DAPI; blue), and 
Aß42 (4G8; green) as well as NETs (MPO; magenta) without NET addition. Arrows highlight specific MPO or 
Aß42 staining. Scale = 50 µM. N=1 
 
Microglia interacted with both digested NETs and all species of Aß42 (Figure 3.3.9). Image 
analysis showed the colocalisation of MPO (magenta) and Aß42 (green) around the nuclei of 
the microglia stained by DAPI (blue). MPO staining in microglia treated with NETs was 
vesicular, indictive of phagocytosis. When the addition of NETs to the microglia was omitted, 
no MPO was observed to be present in the cells (Figure 3.3.9, c). Furthermore, large 
extracellular Aβ aggregates in oligomeric, fibril, and aggregated species stained strongly for 
MPO indicating that NETs, or MPO, bind to or are incorporated into Aβ aggregates.  
The MPO intensity within Aβ42-positive regions was quantified using Cell Profiler using 
methods described previously (Section 3.3.3). 
 
Figure 3.3.10: Quantification of MPO intensity and Aß42 area when added to mouse derived microglia. (a) 
The intensity of MPO fluorescence as a percentage of the vehicle intensity in wells containing digested NETs. 
Vehicle bars represent the intensity of MPO in wells that had no NET addition. Error bars on the graph represent 
the mean ± SEM of three technical replicates. Significance of results could not be determined due to N = 1. (b) 
Aß42 fluorescence area as a percentage of total image area. Error bars on the graph represent the mean ± SEM of 
three technical replicates. Significance of results could not be determined due to N = 1.   
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MPO intensity in wells with NETs was similar in all species except the monomer, which was 
much lower. Aß42 area was also reasonably consistent for all species, with an exception of the 
fibrillar Aß42. Fluorescence was not detected in vehicle wells.  
 
Figure 3.3.11: Quantification of MPO intensity in Aß42 species when digested NETs are added with Aß42 
to mouse derived microglia. Dark grey vehicle bars represent the intensity of MPO in wells that had no NET 
addition. The intensity of MPO in Aß42 in wells containing digested NETs and Aß42 is represented by light grey 
bars. Error bars on the graph represent the mean ± SEM of three technical replicates. Significance of results could 
not be determined due to N = 1.   
The MPO intensity increased with the size of Aß42 species, with fibrillar Aß42 having the 
highest intensity.  Microglia internalised NETs and Aβ, and large extracellular aggregates were 
strongly positive for MPO, indicating binding. Vehicle wells containing no NETs showed low 
levels of fluorescence. Statistics could not be performed due to only one replicate of the assay 




Chapter 4: Discussion 
 
4.1 SUMMARY OF FINDINGS 
The present study aimed to investigate the interaction of neutrophils and Aß42, as previous 
evidence supports the possibility that they are implicated in the pathogenesis of AD. Contrary 
to the hypothesis, none of the Aß42 species induced NETosis, even when supplemented with 
donor serum or a monoclonal anti-Aß antibody. However, immunocytochemistry and 
fluorescence microscopy revealed binding of all Aß42 species to NETs. Interactions of the fibril 
and aggregate Aß42 with NETs was reduced after MNase digestion, suggesting the binding for 
these species could be mediated by the DNA matrix. Alternately, binding could be mediated by 
NET proteins that are washed away after digestion. Microglia were shown to interact with both 
NETS and all species of Aß42. NETs and Aß42 were seen colocalised in close proximity to 
microglia nuclei, suggesting microglia were phagocytosing NET-Aß42 complexes. 
 
4.2 VALIDATION OF EXPERIMENTAL COMPONENTS   
4.2.1 Formation of Aß42 Species 
It was necessary to confirm the presence of four different species of Aß42 to ensure that any 
species-specific results were valid. Research shows that the number of Aß binding partners 
increases with multimerization state, as each species recognises different molecular features 
(95, 106, 107). Due to their different properties and structures, they may have different 
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interactions with neutrophils and contribute differently to neuroinflammation, therefore, it was 
crucial to be able to analyse each species’ interactions with NETs separately.  
The variability of results in the ThT assay was expected due to the nature of Aß42 aggregation. 
Fibrils have inconsistent growth patterns, forming a range of morphologies (108), and 
aggregates can vary widely in size, which would explain the variable ThT fluorescence. Even 
so, fibrillar and aggregated Aß42 consistently had a 2-10 fold higher ThT fluorescence than 
monomers and oligomers. Lower than expected fluorescence values for the more aggregated 
species were seen initially, so Aß42 was incubated with ThT for at least 30 minutes before 
readings, and this gave more consistent results in the later replicates. The subtle difference 
observed between monomers and oligomers was also expected, as neither of these species 
should have large amounts of ß-sheet structure present that would promote enhanced ThT 
fluorescence.  
It is also important to note that the oligomers are the most variable of all the Aß species as there 
are many potential oligomeric states (109). Because of this, it is harder to form homogenous 
oligomer samples, and the solutions prepared may differ between experiments. This difference 
could be why there have been few therapeutic advancements in Aß-targeted treatment, as the 
neurotoxic oligomers prove the hardest to study.  
Although data from the ThT assay gave good indication that four different species of Aß42 
were being obtained, the data does not give precise structural information. ThT can determine 
the presence of ß-sheets, but it cannot determine the presence of actual fibrillar structure. For 
this reason, electron microscopy was utilised for structural confirmation of the four species, and 
confirmed the presence of four distinct species of Aß42. Fibrillar and aggregated Aß42 species 
were absent from monomeric and oligomeric samples. Results from both assays indicated that 
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aggregates were not contaminating smaller species samples. This finding was important as 
maintaining monomeric and oligomeric Aß42 is notoriously difficult, due to the peptide being 
prone to aggregation.  
It is important to consider that the preparations of Aß42 have an aspect of purity that would not 
be observed biologically. This consideration is particularly important for the more aggregated 
forms of Aß42, which  are known to associate with a wide range of proteins present in the CNS.  
Plaques have been shown to be enriched with over 20 different proteins (15), which could 
contribute to binding interactions and chemical properties. Future research may benefit from 
preparing mixed species that are more biologically relevant. Including proteins commonly 
associated with plaques or smaller peptides into Aß preparations could change experimental 
results in comparison to what was observed with individual species alone. However, the present 
study benefited from the purity of the species as it allowed for conclusions about neutrophil 
interactions with Aß specifically.  
 
4.2.2 Isolation of pure neutrophils and induction of NETosis  
Confirming neutrophil purity was critical as it meant that no other types of immune cells could 
be contributing to experimental results or observations. Although the SYTOX™ green assay 
indicated cell death was occurring, this assay could not distinguish between NETosis and other 
cell death mechanisms such as apoptosis and necrosis. Microscopy enabled visualisation of 
typical NET extracellular DNA fibres, and western blotting confirmed abundance of typical 
NET proteins, such as MPO and S100A8, and loss of the cell membrane protein, CD66B. 
Citrullinated histone H3 is most commonly used as the standard marker of NET formation, as 
its presence indicates the decondensation of chromatin has occurred (39). Detection of this 
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protein modification in the digested NET samples was attempted; however, histones are cleaved 
by elastase during the later phases of PMA-induced NETosis, and it is likely that in samples 
where NETosis was complete, this modification could not be detected (110). Regardless, it was 
still concluded that NET formation was successful due to visual observations of long 
extracellular fibres in the fluorescent microscopy images (Figure 3.2.4). This morphology is 
typical of NETs, and would likely not be observed if cells were only undergoing necroptosis or 
apoptosis. In future replicates, staining for citrullinated histone H3 in the NET lawn assays 
could be an effective way of detecting the protein and further confirming NET formation.  
It is also important to consider that PMA is not physiologically relevant, and although it can 
quickly induce NETosis, it is unknown if the NETs produced are representative of what is seen 
biologically. NETs induced by different stimuli in vitro have been shown to be heterogenous 
in protein composition and protein modifications (102). However, there are few non-bacterial 
inducers of NETosis, so PMA was necessary to ensure NETs could be generated without 
causing contamination of cultures. Furthermore, PMA was used primarily as a positive control 
for NETosis in the SYTOX™ green assay (Figure 3.2.3), and to generate NET lawns later on, 
rather than being used to determine mechanisms of NETosis. PMA was therefore considered 
an efficient and appropriate stimulus to use. 
 
4.3 Aß42 DOES NOT CAUSE NETOSIS  
Zenaro et al. confirmed the formation of NETs in the AD brain by observing the colocalization 
of MPO, neutrophil elastase and citrullinated histone H3 around amyloid plaques (39). As they 
found the proximity of NETs to the plaques was not statistically random (39), it is possible that 
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the plaques induce NETosis. The main component of plaques is Aß42, leading to the hypothesis 
that Aß42 would cause NETosis in vitro. Contrary to this hypothesis, none of the four species 
of Aß42 induced NETosis, even when supplemented with serum or a monoclonal antibody 
against Aß (Figure 3.3.1). The peptides’ inability to induce NETosis in the in vitro system used 
in this study suggests there is an external factor playing a role in NET formation around Aß 
plaques in AD. If the Aß42 itself is unable to promote an immune response, potentially other 
components of the plaques, or completely unrelated components, are inducing NETosis.  
This finding contributes to the already controversial literature about the ability of Aß to cause 
an immune response. The present study agrees with previous research by Baik et al., who 
showed neutrophils did not migrate towards Aß alone in vivo (40), and Smyth et al. 
(unpublished research) who observed that Aß does not cause an immune response in vitro in 
other brain cells, such as pericytes. However, another study has found that incubation of Aß 
with anti-Aß specific antibodies leads to increased complement activation and opsonization of 
Aß in vivo (111). In the present study, when neutrophils were incubated with anti-Aß (4G8), 
NETosis was still not observed. This lack of response may be due to invariant regions of the 
murine 4G8 antibody not being recognised by the human Fc receptors in the neutrophils.  
As discussed previously, plaques do not consist solely of Aß, and can be enriched with hundreds 
of different proteins (15, 16). Many of these proteins seem to be consistently abundant across 
AD cases (15, 16) and could be potential contributors to NETosis. Alternately, viral 
components in the plaques could be mediating NETosis (92, 93). Although initially thought to 
be a functionless by-product, Aß has been reported to contribute to the innate immune response 
in bacterial, viral, and fungal infections (91). Infection of the brain with herpes simplex virus-
1 has been shown to rapidly seed fibrilization of the peptide (92, 93). Viral components have 
been found in the AD brain, and Aß42 has been shown to enhance neutrophil immune response 
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to viruses (92, 112, 113). Potentially, the Aß plaque formation is seeded by viral components, 
and the neutrophil immune response is actually triggered by viruses’ underlying plaques.  
Another possible explanation for the lack of NETosis seen in vitro is that neutrophils form 
NETs as a response to inflammatory signals released by microglia surrounding the Aß plaques. 
Microglia have been shown to interact with and phagocytose multiple forms of Aß, and are 
found clustered around the sites of amyloid plaques in the AD brain (33, 34). Microglia have 
also been shown to take on a damage-associated microglia (DAM) phenotype when in close 
proximity to amyloid plaques (44, 45). This phenotype promotes changes in gene expression 
and release of proinflammatory complement and cytokines (45). Cytokines such as IL-8, IL-1ß 
and TNFα have been shown to promote NET release in vitro (114). As Baik et al. found that 
Aß alone was not able to recruit neutrophils (40), it is possible microglia releasing cytokines or 
complement system components may promote neutrophil migration towards plaques and 
eventual NET release. The present study supports a NET-plaque complex interaction with 
microglia, as interactions of microglia with both digested NETs and all Aß42 species were 
observed.  
 
4.4 BINDING INTERACTION OF Aß42 AND NETs 
The second hypothesis, that a binding interaction is occurring between NETs and Aß42, was 
supported by fluorescent images showing the colocalisation of DAPI-labelled NETs and all of 
the species of Aß42. As Aß42 was not present in uncoated wells, or areas where NETs had been 
sloughed off, this suggests the colocalisation was due to binding between the pair. This binding 
agrees with previous studies that show the colocalisation of NETs around Aß plaques in the AD 
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brain (39, 83). Although large amounts of autofluorescence were observed in these results, there 
is literature indicating that eosinophils are autofluorescent (115, 116), providing a sufficient 
explanation for the background, and confidence that the signal was not non-specific antibody 
binding. To counter this autofluorescence, a third channel was imaged without additional stains 
to detect autofluorescence, and this was subtracted from the Aß42 images for quantification. 
The ability to detect and mask regions of autofluorescence allowed Aß42 deposition to be 
accurately identified and quantified. 
The present study examines the specificity of the binding in a way not previously investigated. 
It was found that the more aggregated Aß42 binding seems to be mediated by the DNA matrix 
component of the NETs, as when this was digested away, binding was reduced. This finding 
suggests the NET-plaque complexes found in the AD brain could be mediated primarily by an 
Aß interaction with NET DNA. In a typical immune response when tissue inflammation is 
resolved, NETs are degraded; however, it is possible the plaque structure makes the NET DNA 
difficult to access for digestion by proteases or nucleases such as DNase. If so, NETs may 
persist around plaques because the strong interaction may prevent NETs from being easily 
degraded. It is important to note that the MNase digestion degrades the NET matrix to such an 
extent that most of the structure is lost. Due to this loss of structure, proteins that were part of 
the insoluble DNA matrix may become soluble, and be washed off along with the degraded 
nucleic acids. Therefore, a specific interaction of Aß42 and NET proteins cannot be ruled out, 
as it is possible that some of the proteins may have interactions with the Aß42 that promote 
binding. However, it can be concluded that unlike the less aggregated Aß42 species, the binding 
of the fibrillar and aggregated Aß42 to the NET lawns was mediated by the NETs themselves.  
Another possible explanation for the lack of success of anti-Aß therapies is that NETs around 
the plaques could protect the Aß from being targeted by molecules designed to remove them. 
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If NETs are coating the plaques, molecules designed to target Aß, such as Aß antibodies, would 
not be able to bind effectively and initiate a response.  
These results also give a possible explanation for why the initial immobilised Aß42 binding 
assay was not successful. If the binding was mediated by the DNA matrix for more aggregated 
species, the digested NET samples added to the immobilised Aß42 plates would not contain 
sufficient DNA structure for binding.  
In contrast to the more aggregated species of Aß42, significant amounts of the monomeric and 
oligomeric forms of the peptide were still seen present in wells, even after MNase digestion. 
These smaller Aß42 species have been shown to have a propensity to incorporate themselves 
into membranes (95, 117, 118). Oligomeric incorporation into neuronal membranes disrupts 
membrane fluidity (117) and is why oligomers are now considered the most toxic form of Aß. 
The ring-like patterns of monomeric and oligomeric Aß42 binding to neutrophils is consistent 
with these smaller Aß species interacting with neutrophil membranes.  
 
4.4.1 Microglial response to NETs and Aß42 
When NETs and Aß42 species were added to primary microglia, they were seen to cluster 
around the microglial nuclei, suggesting the phagocytosis of NETs and all species of Aß42. 
Aß42 extracellular aggregates too large for phagocytosis were seen to colocalise with MPO, 
potentially indicating either Aß42-MPO binding or even the formation of Aß42-NET 
complexes. This colocalisation further supports the evidence for a binding interaction between 
Aß42 and NETs. These results show that microglia seem to be interacting with Aß42 and NET 
components, and previous literature has observed the clustering of microglia around Aß plaques 
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(119). Potentially the microglia recognition of the NET-plaque complexes could contribute to 
the neuroinflammation seen in the AD brain.  
It is important to note these results were obtained using mouse microglia, which may show 
different responses to stimuli than human microglia. In particular, the phagocytotic response 
observed may dramatically differ in microglia from AD patients. This is due to the fact that 
microglia in sAD cases have been shown to undergo downregulation of Aß phagocytosis 
receptors, possibly due to increased cytokine concentrations (33). There is evidence that 
sustained exposure to Aß, cytokines, and inflammatory mediators seems to be responsible for 
persistent functional impairment of microglial cells at plaque sites (51).  
 
4.5 LIMITATIONS OF THE STUDY 
The main limitation to this study is the use of a simple in vitro system to investigate the complex 
AD brain environment. All experiments in this study are two dimensional and specifically look 
at Aß42 – NET interactions alone. However, in the AD brain environment there are many more 
cells and extracellular components that are likely to be contributing to the interaction 
mechanism, such as neurons, microglia, the extracellular matrix, and inflammatory signals. 
Potentially these external factors contribute to the NETosis seen in the brain, explaining the 
negative result of the experiment testing if Aß42 causes NETosis. Many AD studies utilise 
mouse models of AD to give more physiological significance to results, but they were not 
available for the present study. However, mouse models would not allow for clear visualisation 
of the interaction investigated in this study, and the in vitro system was useful for isolating the 
interaction between Aß42 and NETs more specifically.  
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Another limitation to the study was the fact that only healthy blood donors were used for 
neutrophil isolation. Neutrophils have been recently identified to take on variable phenotypes 
(120), and so cells from diseased individuals, or AD patients, may produce different responses 
to Aß from the findings of this study. Dong et al. found increased ROS levels and increased 
presence of NETs in whole blood samples from AD patients, and concluded this was associated 
with neutrophil hyperactivation (81). Further studies on isolated neutrophils from individuals 
with AD would be of interest to compare to the results from this study where neutrophils were 
obtained from healthy individuals only.   
Finally, the low number of experimental replicates in some of the assays limits the study. The 
microglia assay (section 3.3.4) contained only one replicate, so the quantitative results may 
differ dramatically after further repeats. However, due to time limitations of the project and the 
difficulty of obtaining and maintaining microglial cultures, further replicates were not able to 
be completed within the assessment timeline.  
 
4.6 FUTURE RESEARCH 
One of the key hypotheses of this study, that Aß42 causes NETosis, was not supported by the 
results, raising the question of what is causing this immune response in the AD brain. As 
previous studies have shown that preventing neutrophil infiltration or neutrophil depletion leads 
to improved cognition in AD models (39, 83), it is possible the NETs are playing a role in the 
neurodegeneration and dementia symptoms seen in late stage AD. However, blocking 
neutrophil function altogether, or depleting these abundant white blood cells would not be 
optimal for AD patients, as neutrophils are the first responders in the immune system to 
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pathogens and tissue damage in the body. Reducing neutrophils would make individuals subject 
to increased chances of infection. It would be more effective to treat AD patients without 
compromising their immune systems, which are already diminished due to old age (121). 
Potentially, treatment could involve targeting NET release in the brain specifically. Alternately, 
therapies could target NETs and promote their degradation in the brain once they had formed. 
To be able to develop these therapies, finding what is causing the release and strong binding of 
NETs around Aß plaques is essential. 
To investigate the primary cause of  NETosis in the brain, the assay used in the present study 
(Section 2.3.8) could be altered to derive more clinically relevant results. For one specific 
donor, some NETosis occurred when their neutrophils were incubated with Aß42 aggregates 
and serum (Figure 3.3.1), which suggests some individuals may have Aß antibodies that 
encourage a neutrophil immune response. To confirm this theory, further experimental 
replicates would have to be carried out with this specific donor to confirm the result was not a 
false positive. Furthermore, the assay could be repeated using AD patient derived neutrophils, 
to see if any NETosis occurs. If substantial cell death was seen in replicates of this assay using 
AD patient samples, this could indicate the presence of anti-Aß antibodies that would be 
potential therapeutic targets for inhibiting NETosis. It would also be of interest to match the 
results of this study with Aß deposition in AD individuals, using positron emission tomography 
(PET) imaging, to see if there is a correlation between plaque load and levels of NETosis. This 
would complement the recent study by Dong et al. that found inflammatory properties of 
neutrophils change as the percentage of aged neutrophils expands in AD patients, and also that 
neutrophil phenotype may correlate with cognitive decline (81).  
Further replicates of the Aß42-NET binding assay would also be beneficial to see if more 
repeats would find a statistically significant difference between Aß42 binding to NETs and 
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MNase treated NETs. Dependent on this result, the specifics of the interaction could be 
investigated further using the same fluorescent assay (Section 2.3.10), but using antibodies to 
target the presence of common NET proteins and their relative location in comparison to the 
bound Aß42. A future step would be to obtain human brain tissue from control and AD patients, 
and stain sections for the presence of NET makers and Aß plaques. Zenaro et al. were able to 
see the colocalisation of citrullinated histone H3 with Aß plaques in human brain tissue (39), 
but did not investigate the specific binding of the pair, which would be important for developing 
targeted treatment.  
Finally, to see if microglia uptake of Aß42 and NETs was significant, further replicates of the 
fluorescence assay would be required (Figure 3.3.9). It would also be of interest to investigate 
levels of inflammatory signals released by microglia in the presence of NETs and Aß to see if 
the phagocytosis of these species is promoting neuroinflammation.  
 
4.7 CONCLUSION  
Although Aß42 did not induce NETosis in this in vitro study, strong binding interactions 
between NETs and all species of Aß42 were observed. Binding between fibrillar and aggregated 
Aß42 to NETs seems to be mediated predominantly by the NET DNA matrix, possibly 
representing the binding interaction seen between NETs and Aß plaques. Both NETs and Aß42 
were phagocytosed by microglia, suggesting the resident immune cells of the brain may 
recognise these as molecules that need clearance.  
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Due to previous evidence (8) and the lack of immune response of neutrophils to Aß42 in this 
study, it is possible Aß plaques are primarily inert in early stages of AD. Furthermore, research 
shows individuals can have significant amounts of Aß deposition, without presenting with 
dementia symptoms, suggesting that plaque load is not correlated with neurodegeneration (24). 
Previous theories have suggested an early amyloid-dependent phase, and later amyloid-
independent phase of AD (122). The early stage involves Aß accumulation over time; however, 
once the second stage is triggered, Aß is no longer required, and it is at this point that individuals 
start experiencing severe dementia symptoms (122). Due to many genes implicated in sAD 
being related to immunity, it is possible that the second stage Aß-independent 
neurodegeneration could be an effect of ongoing inflammation.  
Strokes and traumatic brain injury (TBI) are correlated with the onset of AD, and both can 
cause significant BBB damage and leakage (86). A weakened BBB can allow access for 
immune cells, such as neutrophils, to infiltrate the brain parenchyma. Therefore, the infiltration 
of neutrophils and subsequent formation of NETs around Aß plaques could be key in driving 
the neuroinflammation and dementia systems seen in the late stages of AD. Roy et al. found Aß 
plaques were immunogenic only when associated with nucleic acids (46), which could support 
hypotheses that NET formation changes the immune response to Aß plaques. Oxidative 
proteins, such as MPO, that are associated with NETs, may potentially alter Aß chemical 
structure, therefore modifying plaque properties and initiating changes in inflammation.  
Lack of success in the development of Aß-focused therapeutics, and the overwhelming 
evidence for immune system contributions to AD, indicate that successful treatment could lie 
in inhibiting inflammatory pathways that contribute to progression towards later stages of the 
disease. Future treatments based around preventing inflammation after Aß deposition may be 
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